WO2024052350A1 - Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease - Google Patents
Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease Download PDFInfo
- Publication number
- WO2024052350A1 WO2024052350A1 PCT/EP2023/074334 EP2023074334W WO2024052350A1 WO 2024052350 A1 WO2024052350 A1 WO 2024052350A1 EP 2023074334 W EP2023074334 W EP 2023074334W WO 2024052350 A1 WO2024052350 A1 WO 2024052350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adpkd
- family
- kidney disease
- treatment
- days
- Prior art date
Links
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 title claims abstract description 60
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title description 31
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title description 3
- 108091007267 Dopamine D1-Like Receptors Proteins 0.000 title 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 claims abstract description 34
- 102000015554 Dopamine receptor Human genes 0.000 claims abstract description 34
- 239000000556 agonist Substances 0.000 claims abstract description 21
- 238000012385 systemic delivery Methods 0.000 claims abstract description 17
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical group C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 claims description 26
- 229960002724 fenoldopam Drugs 0.000 claims description 26
- 230000001070 adhesive effect Effects 0.000 claims description 23
- 239000000853 adhesive Substances 0.000 claims description 22
- 229960003179 rotigotine Drugs 0.000 claims description 18
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical group CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 18
- 238000012384 transportation and delivery Methods 0.000 claims description 10
- 230000003204 osmotic effect Effects 0.000 claims description 7
- 230000002459 sustained effect Effects 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 abstract description 22
- 102100036143 Polycystin-1 Human genes 0.000 abstract description 18
- 101710146367 Polycystin-1 Proteins 0.000 abstract description 14
- 230000003291 dopaminomimetic effect Effects 0.000 abstract description 13
- 230000007246 mechanism Effects 0.000 abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 9
- 230000000638 stimulation Effects 0.000 abstract description 9
- 210000004081 cilia Anatomy 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 7
- 238000013459 approach Methods 0.000 abstract description 5
- 230000008753 endothelial function Effects 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 208000028782 Hereditary disease Diseases 0.000 abstract description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract description 2
- 208000024556 Mendelian disease Diseases 0.000 abstract description 2
- 208000011728 renal alteration Diseases 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 description 67
- 239000003814 drug Substances 0.000 description 52
- 229940079593 drug Drugs 0.000 description 39
- 239000011159 matrix material Substances 0.000 description 28
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 239000000178 monomer Substances 0.000 description 21
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 18
- 229920001296 polysiloxane Polymers 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 238000013271 transdermal drug delivery Methods 0.000 description 17
- -1 polybutylene Polymers 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102100036142 Polycystin-2 Human genes 0.000 description 11
- 239000012790 adhesive layer Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000005060 rubber Substances 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 210000003038 endothelium Anatomy 0.000 description 10
- 125000000524 functional group Chemical group 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229920000058 polyacrylate Polymers 0.000 description 7
- 210000002321 radial artery Anatomy 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000035485 pulse pressure Effects 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 101710146368 Polycystin-2 Proteins 0.000 description 5
- 229920002367 Polyisobutene Polymers 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003975 mesenteric artery Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 108010004408 TRPP Cation Channels Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000002998 adhesive polymer Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 150000002121 epoxyeicosatrienoic acids Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 3
- 101000865210 Homo sapiens D(1B) dopamine receptor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000004218 vascular function Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- JKPISQIIWUONPB-HNNXBMFYSA-N (-)-stepholidine Chemical compound C1CN2CC(C(=C(O)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 JKPISQIIWUONPB-HNNXBMFYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100020802 D(1A) dopamine receptor Human genes 0.000 description 2
- 102100029813 D(1B) dopamine receptor Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 description 2
- 229920002633 Kraton (polymer) Polymers 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101100388144 Xenopus laevis drd5 gene Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001253 acrylic acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012301 transgenic model Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940117958 vinyl acetate Drugs 0.000 description 2
- SUHGRZPINGKYNV-GJZGRUSLSA-N (1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-2-benzopyran-5,6-diol Chemical compound C1([C@H]2O[C@H](C3=CC=C(O)C(O)=C3C2)CN)=CC=CC=C1 SUHGRZPINGKYNV-GJZGRUSLSA-N 0.000 description 1
- BWHPNJVKFAPVOG-QYFJGNGUSA-N (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13[C@H]1O[C@@H](CN)C2=CC=C(O)C(O)=C2C1 BWHPNJVKFAPVOG-QYFJGNGUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BGOQGUHWXBGXJW-YOEHRIQHSA-N (6as,12br)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol Chemical compound N1CC2=CC=CC=C2[C@@H]2[C@@H]1CCC1=C2C=C(O)C(O)=C1 BGOQGUHWXBGXJW-YOEHRIQHSA-N 0.000 description 1
- QDUNOUQOKOYLCH-MLGOLLRUSA-N (6as,12br)-6a,7,8,12b-tetrahydro-6h-chromeno[3,4-c]isoquinoline-2,3-diol Chemical compound N1CC2=CC=CC=C2[C@H]2[C@H]1COC1=C2C=C(O)C(O)=C1 QDUNOUQOKOYLCH-MLGOLLRUSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- AHVCKSSYNJYSIQ-UHFFFAOYSA-N 1-hydroxypentyl 2-methylprop-2-enoate Chemical compound CCCCC(O)OC(=O)C(C)=C AHVCKSSYNJYSIQ-UHFFFAOYSA-N 0.000 description 1
- MIYFFZILCMZNRY-UHFFFAOYSA-N 1-hydroxypentyl prop-2-enoate Chemical compound CCCCC(O)OC(=O)C=C MIYFFZILCMZNRY-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- PVVATGNFHKTPTA-UHFFFAOYSA-N 1-methylsulfinyloctane Chemical compound CCCCCCCCS(C)=O PVVATGNFHKTPTA-UHFFFAOYSA-N 0.000 description 1
- JUDKOGFHZYMDMF-UHFFFAOYSA-N 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=CC=C1 JUDKOGFHZYMDMF-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- CHNGPLVDGWOPMD-UHFFFAOYSA-N 2-ethylbutyl 2-methylprop-2-enoate Chemical compound CCC(CC)COC(=O)C(C)=C CHNGPLVDGWOPMD-UHFFFAOYSA-N 0.000 description 1
- JGRXEBOFWPLEAV-UHFFFAOYSA-N 2-ethylbutyl prop-2-enoate Chemical compound CCC(CC)COC(=O)C=C JGRXEBOFWPLEAV-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- IEVADDDOVGMCSI-UHFFFAOYSA-N 2-hydroxybutyl 2-methylprop-2-enoate Chemical compound CCC(O)COC(=O)C(C)=C IEVADDDOVGMCSI-UHFFFAOYSA-N 0.000 description 1
- ZKYCLDTVJCJYIB-UHFFFAOYSA-N 2-methylidenedecanamide Chemical compound CCCCCCCCC(=C)C(N)=O ZKYCLDTVJCJYIB-UHFFFAOYSA-N 0.000 description 1
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- QDKUSZZMIFQVPN-UHFFFAOYSA-N 4-(4,5,6,7-tetrahydrothieno[2,3-c]pyridin-4-yl)benzene-1,2-diol Chemical compound C1=C(O)C(O)=CC=C1C1C(C=CS2)=C2CNC1 QDKUSZZMIFQVPN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NDWUBGAGUCISDV-UHFFFAOYSA-N 4-hydroxybutyl prop-2-enoate Chemical compound OCCCCOC(=O)C=C NDWUBGAGUCISDV-UHFFFAOYSA-N 0.000 description 1
- YHLGDDZHAYHGHC-UHFFFAOYSA-N 5-phenyl-1,2,3,4,4a,5,6,6a-octahydrobenzo[h]isoquinoline-7,8-diol Chemical compound C12CCNCC2=C2C=CC(O)=C(O)C2CC1C1=CC=CC=C1 YHLGDDZHAYHGHC-UHFFFAOYSA-N 0.000 description 1
- KKZGFVAZUKHFAC-UHFFFAOYSA-N 6-br-apb Chemical compound C1N(CC=C)CCC=2C(Br)=C(O)C(O)=CC=2C1C1=CC=CC=C1 KKZGFVAZUKHFAC-UHFFFAOYSA-N 0.000 description 1
- XFOFBPRPOAWWPA-UHFFFAOYSA-N 6-hydroxyhexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCO XFOFBPRPOAWWPA-UHFFFAOYSA-N 0.000 description 1
- OCIFJWVZZUDMRL-UHFFFAOYSA-N 6-hydroxyhexyl prop-2-enoate Chemical compound OCCCCCCOC(=O)C=C OCIFJWVZZUDMRL-UHFFFAOYSA-N 0.000 description 1
- NQSLZEHVGKWKAY-UHFFFAOYSA-N 6-methylheptyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C(C)=C NQSLZEHVGKWKAY-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GHWJEDJMOVUXEC-UHFFFAOYSA-N 9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1NCCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 GHWJEDJMOVUXEC-UHFFFAOYSA-N 0.000 description 1
- HJWHHQIVUHOBQN-UHFFFAOYSA-N 9-chloro-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C1N(CC=C)CCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 HJWHHQIVUHOBQN-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010036221 Aquaporin 2 Proteins 0.000 description 1
- 102100034414 Aquaporin-2 Human genes 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- XYJQBHCHAZPWHA-UHFFFAOYSA-N CC(C)C([CH2-])=O Chemical compound CC(C)C([CH2-])=O XYJQBHCHAZPWHA-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000015121 Cardiac valve disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 102400000060 Copeptin Human genes 0.000 description 1
- 101800000115 Copeptin Proteins 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 101150110160 DRD1 gene Proteins 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 102100037927 DnaJ homolog subfamily B member 11 Human genes 0.000 description 1
- 101150091394 Drd5 gene Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101000805858 Homo sapiens DnaJ homolog subfamily B member 11 Proteins 0.000 description 1
- 101001072765 Homo sapiens Neutral alpha-glucosidase AB Proteins 0.000 description 1
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WRNKIDLXXXIELU-IEBWSBKVSA-N LSM-3788 Chemical compound C1=CC([C@H]2C3=CC=CC=C3CN([C@@H]2C2)C)=C3C2=CNC3=C1 WRNKIDLXXXIELU-IEBWSBKVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- FHYWNBUFNGHNCP-UHFFFAOYSA-N N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide Chemical compound Br.C1N(C)CCC(C(=C(O)C(O)=C2)Cl)=C2C1C1=CC=CC(C)=C1 FHYWNBUFNGHNCP-UHFFFAOYSA-N 0.000 description 1
- 102100036592 Neutral alpha-glucosidase AB Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical group [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 101150056230 PKD1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229920003182 Surlyn® Polymers 0.000 description 1
- 239000005035 Surlyn® Substances 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229950007871 adrogolide Drugs 0.000 description 1
- KTEBZVJGMARTOQ-GCJKJVERSA-N adrogolide Chemical compound CC(=O)OC1=C(OC(C)=O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 KTEBZVJGMARTOQ-GCJKJVERSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- REHAKLRYABHSQJ-KDOFPFPSSA-N chembl28338 Chemical compound OC1=C(O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 REHAKLRYABHSQJ-KDOFPFPSSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- FWLDHHJLVGRRHD-UHFFFAOYSA-N decyl prop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C=C FWLDHHJLVGRRHD-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZQTSNGJHMUKLOM-ZDUSSCGKSA-N dinapsoline Chemical compound C1NCC2=CC=CC3=C2[C@@H]1C1=CC=C(O)C(O)=C1C3 ZQTSNGJHMUKLOM-ZDUSSCGKSA-N 0.000 description 1
- QOHSTVKJXZTEOL-UHFFFAOYSA-N dinoxyline Chemical compound C1NCC2=CC=CC3=C2C1C1=CC=C(O)C(O)=C1O3 QOHSTVKJXZTEOL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 108010038305 down-regulator of transcription 1 Proteins 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002195 fatty ethers Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- SCFQUKBBGYTJNC-UHFFFAOYSA-N heptyl prop-2-enoate Chemical compound CCCCCCCOC(=O)C=C SCFQUKBBGYTJNC-UHFFFAOYSA-N 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000007757 hot melt coating Methods 0.000 description 1
- 102000053594 human TNFRSF10B Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- GJIDOLBZYSCZRX-UHFFFAOYSA-N hydroxymethyl prop-2-enoate Chemical compound OCOC(=O)C=C GJIDOLBZYSCZRX-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003705 neurological process Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- MDYPDLBFDATSCF-UHFFFAOYSA-N nonyl prop-2-enoate Chemical compound CCCCCCCCCOC(=O)C=C MDYPDLBFDATSCF-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940065472 octyl acrylate Drugs 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- ULDDEWDFUNBUCM-UHFFFAOYSA-N pentyl prop-2-enoate Chemical compound CCCCCOC(=O)C=C ULDDEWDFUNBUCM-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000023568 response to fluid shear stress Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- SYHALWYYSDMSLE-UHFFFAOYSA-N skf-89,145 Chemical compound C1=2C=CSC=2CN(C)CC1C1=CC=C(O)C(O)=C1 SYHALWYYSDMSLE-UHFFFAOYSA-N 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- KEROTHRUZYBWCY-UHFFFAOYSA-N tridecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C(C)=C KEROTHRUZYBWCY-UHFFFAOYSA-N 0.000 description 1
- XOALFFJGWSCQEO-UHFFFAOYSA-N tridecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C=C XOALFFJGWSCQEO-UHFFFAOYSA-N 0.000 description 1
- WRTMQOHKMFDUKX-UHFFFAOYSA-N triiodide Chemical compound I[I-]I WRTMQOHKMFDUKX-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Definitions
- the present invention is in the field of kidney disease.
- the present invention relates to methods and pharmaceutical compositions for the treatment of autosomal dominant polycystic kidney disease using a D1-like family of dopamine receptors agonist through a continuous systemic delivery.
- ADPKD Autosomal dominant polycystic kidney disease
- ADPKD patients present a progressive impairment of kidney function related to the development of multiple renal cysts, typically leading to end- stage renal disease around the age of 55 to 65 years. Irrespective of decreased kidney function, ADPKD is also characterized by an increase in cardiovascular diseases. In particular, ADPKD patients develop arterial hypertension at an early stage of the disease, as well as various left ventricular hypertrophy, cardiac valvulopathies, intracranial aneurysms, and aortic dissections (1,2) . In addition, patients with ADPKD display an altered cardiovascular adaptation to exercise (3) and also after surgical creation of arterio-venous fistula (AVF) as a native vascular access for hemodialysis in end-stage renal disease (4) .
- APF arterio-venous fistula
- PTD1 polycystin 1
- PWD2 Polycystin-2
- Polycystin-1 is a transmembrane protein with a large extracellular domain acting as a sensor of mechanical stimuli, with an intracellular domain that interacts with the transient receptor potential channel polycystin-2 (TRPP2), assembled at the membrane in a 1:3 ratio (5) .
- TRPP2 transient receptor potential channel polycystin-2
- These proteins form a complex at the primary cilium of renal epithelial cells, sensing flow variation and promoting calcium entry to control cell function and proliferation. The alteration in this pathway contributes to promote cystogenesis in ADPKD patients (6) .
- increasing evidence suggests that the cardiovascular complications of ADPKD are a direct consequence of the presence of abnormal polycystins in vascular cells (7, 8, 9) .
- the present invention relates to the use of a continuous systemic delivery of D1-like family of dopamine receptors agonist for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
- ADPKD autosomal dominant polycystic kidney disease
- ADPKD autosomal dominant polycystic kidney disease
- Stimulation of endothelial type 5 dopamine receptors (DR5) can acutely compensate for the endothelial consequences of polycystin deficiency, but the chronic impact of this approach has to be evaluated in ADPKD.
- the inventor’s study performed in patients with ADPKD supports the hypothesis that the stimulation of the dopaminergic system, in particular D1-like family of dopamine receptors, may improve endothelial function by restoring cilia length and mechanotransductory capacity (10) .
- the inventors carefully assess whether the deficiency in endothelial polycystin-1 and cilia promotes or potentiates both cardiovascular and renal alterations, to explore the mechanisms involved, and to propose and test new pharmacological approaches, in particular targeting the dopaminergic system, to prevent complications of ADPKD. Indeed, the inventors demonstrate that in ADPKD patients chronic administration of rotigotine improves conduit artery endothelial function through the restoration of flow-induced NO release as well as hemodynamics, and confirms that endothelial DR5 activation represents a promising pharmacological approach to prevent cardiovascular complications of ADPKD.
- the first object of the present invention relates to a method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a D1-like family of dopamine receptors agonist through a continuous systemic delivery.
- ADPKD autosomal dominant polycystic kidney disease
- the term “subject” denotes a mammal, such as a rodent, a feline, a canine, and a primate.
- the subject according to the invention is a human. More particularly, the subject according to the invention has or is susceptible to have kidney disease, in particular ADPKD.
- ADPKD autosomal dominant polycystic kidney disease
- PKD1 which is the protein encoded by the PKD1 gene, is present on the cilia and is thought to sense the flow with its large extracellular domains, activating the calcium channels associated with PKD2, the product of gene PKD2, as a result of the genetic setting of ADPKD as explained in the genetics sub-section above.
- the different symptoms and signs are, but are not limited to acute loin pain, blood in the urine, ballotable kidneys, subarachnoid hemorrhage (berry aneurysm), hypertension, associated liver cysts, uremia due to kidney failure, anemia due to chronic kidney disease, increase RBC or erythropoietin secretion.
- continuous systemic delivery means the administration continuous of a drug product systemically in the body of the patient. Continuous systemic delivery is preferred in order to achieve prolonged and relatively uniform blood concentrations of the drug.
- flux also called “permeation rate”
- J the flux in g/cm2/sec
- D the diffusion coefficient of the drug through the skin or mucosa in cm2/sec
- dCm/dx the concentration gradient of the drug across the skin or mucosa.
- the continuous systemic delivery is administered with a pump.
- the D1-like family of dopamine receptors agonist is typically administered via a pump (e.g. a portable infusion pump) that delivers D1-like family of dopamine receptors agonist boluses at specific intervals.
- a pump e.g. a portable infusion pump
- Other suitable pumps are e.g. disclosed in the international patent application published under reference WO2007041386 or in U.S. Patents Nos.4,722,734; 5,013,293; 5,312,325; 5,328,454; 5,336,168; and 5,372,579.
- the term “pump” is intended to include any number of drug delivery systems which are capable of dispensing a fluid to a user upon activation.
- Drug pump is configured such that, upon activation by a user by depression of the activation mechanism, the drug pump is initiated to: insert a fluid pathway into the user; enable, connect, or open necessary connections between a drug container, a fluid pathway, and a sterile fluid conduit; and force drug fluid stored in the drug container through the fluid pathway and fluid conduit for delivery into a user.
- One or more optional safety mechanisms may be utilized, for example, to prevent premature activation of the drug pump.
- the drug pump is capable of delivering a range of drugs with different viscosities and volumes.
- the drug pump is capable of delivering a drug at a controlled flow rate (speed) and/or of a specified volume.
- the drug delivery process is controlled by one or more flow restrictors within the fluid pathway connection and/or the sterile fluid conduit.
- other flow rates may be provided by varying the geometry of the fluid flow path or delivery conduit, varying the speed at which a component of the drive mechanism advances into the drug container to dispense the drug therein, or combinations thereof.
- the pump is an osmotic pump.
- the term “osmotic pump” relate to miniature infusion pumps for the continuous dosing of laboratory animals. These minipumps provide researchers with a method for controlled and continuous agent delivery in vivo. Osmotic pumps can be used for systemic administration when implanted subcutaneously or intraperitoneally.
- the pumps can be attached to a catheter to provide targeted delivery for intravenous, intraarterial, intracerebral, or cranial/calvarial infusion.
- the pumps can be used to target delivery to a variety of sites including direct substance administration to cord, spleen, liver, organ or tissue transplants. A single pump may provide up to four weeks of infusion.
- needle is intended to refer to a variety of needles including but not limited to conventional hollow needles, such as a rigid hollow steel needles, and solid core needles more commonly referred to as a “trocars.”
- the needle is a gauge solid core trocar and in other embodiments, the needle may be any size needle suitable to insert the cannula for the type of drug and drug administration (e.g., subcutaneous, intramuscular, intradermal, etc.) intended.
- a sterile boot may be utilized within the needle insertion mechanism.
- the sterile boot is a collapsible sterile membrane that is in fixed engagement at a proximal end with the manifold and at a distal end with the base.
- the sterile boot is maintained in fixed engagement at a distal end between base and insertion mechanism housing.
- Base includes a base opening through which the needle and cannula may pass-through during operation of the insertion mechanism, as will be described further below.
- Sterility of the cannula and needle are maintained by their initial positioning within the sterile portions of the insertion mechanism.
- needle and cannula are maintained in the sterile environment of the manifold and sterile boot.
- the continuous systemic delivery is administered with a transdermal drug delivery system.
- transdermal refers to delivery, administration or application of a drug by means of direct contact with skin or mucosa.
- transdermal drug delivery system refers to a system (e.g., a device) comprising a composition that releases drug upon application to the skin (or any other surface noted above). Thereafter, the drug is dispersed throughout the patient's body by blood circulation.
- the transdermal drug delivery system is a substantially non-aqueous, solid form, capable of conforming to the surface with which it comes into contact, and capable of maintaining such contact so as to facilitate topical application without adverse physiological response, and without being appreciably decomposed by aqueous contact during topical application to a subject.
- Many such systems are known in the art and commercially available, such as transdermal drug delivery patches.
- the transdermal drug delivery systems comprise a drug-containing polymer matrix that comprises a pressure-sensitive adhesive or bioadhesive and drug, and a face adhesive layer disposed on the skin-contacting side of the drug-containing polymer matrix that is adopted for application to a user's (e.g., a subject's) skin.
- the transdermal drug delivery system is a transdermal patch.
- polymer matrix refers to a polymer composition which contains one or more drugs.
- the matrix comprises a pressure-sensitive adhesive polymer or a bioadhesive polymer.
- the transdermal drug delivery system (e.g.
- the transdermal patch consists of a backing layer, a single drug-containing polymer matrix layer, a single face adhesive layer, and, optionally, a release liner that is removed prior to use.
- the transdermal drug delivery system e.g. the transdermal patch
- the transdermal drug delivery system may be packaged or provided in a package, typically a peelable pouch, as is used in the art for transdermal drug delivery systems in general.
- a wide variety of materials known to those skilled in the art of transdermal drug delivery may be used as pouchstock materials, including Surlyn® packaging resins (ethylene acid copolymers) sold by DuPont®, Wilmington, Del. Face Adhesive
- the transdermal drug delivery system e.g.
- the transdermal patch) described herein may comprise a skin-contacting face adhesive layer, separate from the drug-containing polymer matrix.
- the face adhesive comprises a rubber-based polymer, such as a rubber-based pressure sensitive adhesive, such as a polyisobutylene or styrene-isoprene-styrene polymer, optionally formulated with a tackifier or plasticizer to provide pressure-sensitive adhesive properties.
- suitable rubber-based polymers and rubber-based pressure-sensitive adhesives include natural or synthetic polyisoprene, polybutylene, polyisobutylene, styrene-butadiene polymers, styrene-isoprene-styrene block copolymers, hydrocarbon polymers, such as butyl rubber, halogen-containing polymers, such as polyacrylic-nitrile, polytetrafluoroethylene, polyvinylchloride, polyvinylidene chloride, and polychlorodiene, and other copolymers thereof.
- polyisobutylene pressure-sensitive adhesive polymers such as DURO-TAK® 87-6908 (Henkel), which comprises polyisobutylene polymer and tackifier.
- polyisobutylene pressure-sensitive adhesive polymers such as DURO-TAK® 87-6908 (Henkel)
- styrene-isoprene-styrene block copolymers such as Kraton® D1111 KT (Kraton Performance Polymers, Inc.).
- the face adhesive layer may comprise a single rubber-based pressure-sensitive adhesive, or a blend of two or more adhesives.
- the face adhesive layer may comprise one or more tackifiers, plasticizing agents (such as mineral oil, hydrogenated hydrocarbon resins, aliphatic resins, rosins, and terpenes), and/or other components selected to confer satisfactory physical stability, chemical stability, and/or skin adhesion, as discussed in more detail below.
- the face adhesive layer may comprise at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% by dry weight of the one or more rubber-based pressure sensitive adhesives.
- “% by dry weight of the one or more rubber-based pressure sensitive adhesives” includes the dry weight of the rubber-based polymer and any tackifiers and/or plasticizers included in the composition.
- the face adhesive layer may be applied at a coat weight of from 2 to about 20 mg/cm2, including at from about 5 to about 10 mg/cm2, including 5 mg/cm2, 6 mg/cm2, 7 mg/cm2, 8 mg/cm2, 9 mg/cm2, or 10 mg/cm2, or any coat weight there between.
- coat weight refers to the weight of the layer at issue per unit area of the active surface area of the transdermal drug delivery system (e.g. the transdermal patch).
- Drug-Containing Polymer Matrix The compositions described herein comprise a polymer matrix that is suitable for use with the therapeutic agent (e.g. the D 1 -like family receptor agonist) being formulated.
- Typical polymers used in a polymer matrix for a transdermal drug delivery system include pressure-sensitive adhesive acrylic polymers, silicone-containing polymers, and rubber-based polymers (such as polyisobutylene and styrene-isoprene-styrene polymers).
- suitable polymers are set forth below.
- the term “acrylic polymer” is used here as in the art interchangeably with “polyacrylate” “polyacrylic polymer” and “acrylic adhesive”.
- Suitable acrylic-based polymers include homopolymers, copolymers, terpolymers, and the like of various acrylic acids or esters. In some embodiments, acrylic-based polymers are adhesive polymers.
- acrylic- based polymers function as an adhesive by the addition of tackifiers, plasticizers, crosslinking agents or other additives.
- acrylic polymers used in transdermal drug delivery systems include polymers of one or more monomers of acrylic acids and other copolymerizable monomers, copolymers of alkyl acrylates and/or methacrylates and/or copolymerizable secondary monomers or monomers with functional groups, and combinations of acrylic-based polymers based on their functional groups.
- Acrylic-based polymers having functional groups include copolymers and terpolymers which contain, in addition to nonfunctional monomer units, further monomer units having free functional groups, where the monomers can be monofunctional or polyfunctional.
- the acrylic polymer is composed of at least 50% by weight of an acrylate or alkyl acrylate monomer, from 0 to 20% of a functional monomer copolymerizable with the acrylate, and from 0 to 40% of other monomers.
- Typical acrylate monomers include acrylic acid and methacrylic acid and alkyl acrylic or methacrylic esters such as methyl acrylate, ethyl acrylate, propyl acrylate, amyl acrylate, butyl acrylate, butyl methacrylate, hexyl acrylate, methyl methacrylate, hexyl methacrylate, heptyl acrylate, octyl acrylate, nonyl acrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacryl
- Typical non-functional acrylic-based polymers include any acrylic based polymer having no or substantially no free functional groups.
- “functional monomers or groups” are monomer units typically in acrylic- based polymers which have reactive chemical groups which modify the acrylic-based polymers directly or which provide sites for further reactions. Examples of functional groups include carboxyl, epoxy, hydroxyl, sulfoxyl, and amino groups.
- Acrylic-based polymers having functional groups contain, in addition to the nonfunctional monomer units described above, further monomer units having free functional groups. As noted above, the monomers can be monofunctional or polyfunctional.
- Typical carboxyl functional monomers include acrylic acid, methacrylic acid, itaconic acid, maleic acid, and crotonic acid.
- Typical hydroxyl functional monomers include 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate, hydroxymethyl acrylate, hydroxymethyl methacrylate, hydroxyethyl acrylate, hydroxyethyl methacrylate, hydroxypropyl acrylate, hydroxypropyl methacrylate, hydroxybutyl acrylate, hydroxybutyl methacrylate, hydroxyamyl acrylate, hydroxyamyl methacrylate, hydroxyhexyl acrylate, hydroxyhexyl methacrylate.
- amide-group containing-monomers such as octyl acrylamide
- vinyl group containing monomers such as vinyl acetate and vinyl pyrrolidone
- the functionality of the polymer(s) is selected depending on the drug being formulated, e.g., is selected based on whether the functional group is reactive or non- reactive with a functional group on the drug being formulated.
- Suitable acrylic polymers also include pressure-sensitive adhesives which are commercially available, such as the acrylic-based adhesives sold under the trademarks DURO-TAK® and GELVA® by Henkel Corporation, Bridgewater, N.J.
- Suitable acrylic adhesives include those sold under the trademark EUDRAGIT® by Evonik Industries AG, Essen Germany.
- hydroxy functional adhesives with a reactive functional OH group can be used, including GELVA® 737, 788, and 1151, and DURO-TAK® 87-2287, -4287, -2510 and -2516.
- the drug-containing polymer matrix comprises a silicone-based polymer.
- silicone-based polymer is used interchangeably with the terms silicon polymers, siloxane, polysiloxane, and silicones as used herein and as known in the art.
- a suitable silicone-based polymer may also be a pressure-sensitive adhesive.
- the silicone-based polymer is an adhesive polymer.
- the silicone-based polymer functions as an adhesive by the addition of tackifiers, plasticizers, crosslinking agents, or other additives.
- Suitable polysiloxanes include silicone pressure-sensitive adhesives which are based on two major components: (i) a polymer or gum and (ii) a tackifying resin.
- a polysiloxane adhesive can be prepared by cross-linking a gum, typically a high molecular weight polydiorganosiloxane, with a resin, to produce a three-dimensional silicate structure, via a condensation reaction in an appropriate organic, volatile solvent, such as ethyl acetate or heptane.
- the ratio of resin to polymer can be adjusted in order to modify the physical properties of polysiloxane adhesives.
- Sobieski, et al. “Silicone Pressure Sensitive Adhesives,” Handbook of Pressure-Sensitive Adhesive Technology, 2nd ed., pp.508-517 (D. Satas, ed.), Van Nostrand Reinhold, New York (1989).
- Exemplary silicone-based polymers are adhesives (e.g., capable of sticking to the site of topical application), including pressure-sensitive adhesives.
- Illustrative examples of silicone-based polymers having reduced silanol concentrations include silicone-based adhesives (and capped polysiloxane adhesives) such as those described in U.S. Pat. No.
- BIO-PSA® 7-4100, -4200 and -4300 product series and non- sensitizing, pressure-sensitive adhesives produced with compatible organic volatile solvents (such as ethyl acetate or heptane) and available commercially under their BIO-PSA® 7-4400 series, -4500 series, such as -4502, and -4600 series.
- compatible organic volatile solvents such as ethyl acetate or heptane
- the drug-containing polymer matrix comprises one or more rubber-based polymers, such as one or more rubber-based pressure-sensitive adhesives, such as any one or more of those discussed above in the context of the face adhesive.
- the polymer matrix and/or face adhesive layer may comprise an antioxidant.
- the antioxidant may be one known for use in transdermal drug delivery systems (e.g.
- the transdermal patch such as butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tertiary-butylhydroquinone (TBHQ), ascorbic acid, ascorbyl palmitate, alpha-tocopherol and its esters, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfite, and propyl gallate, and mixtures thereof.
- BHT butylhydroxytoluene
- BHA butylhydroxyanisole
- TBHQ tertiary-butylhydroquinone
- ascorbic acid ascorbyl palmitate
- alpha-tocopherol and its esters alpha-tocopherol and its esters
- fumaric acid malic acid
- sodium ascorbate sodium metabisulfite
- propyl gallate and mixtures thereof.
- the antioxidant may comprise from about 0 to about 1%, including from about 0 to about 0.5% by weight of the polymer matrix face adhesive laye
- the polymer matrix and/or face adhesive polymer may comprise one or more other pharmaceutically acceptable excipients, such as a plasticizer, penetration enhancer, filler, and the like.
- the polymer matrix comprises from about 0% to about 20% of one or more such excipients.
- a “penetration enhancer” is an agent known to accelerate the delivery of the drug through the skin.
- agents also have been referred to as accelerants, adjuvants, and sorption promoters, and are collectively referred to herein as “enhancers.”
- This class of agents includes those with diverse mechanisms of action, including those which have the function of improving percutaneous absorption, for example, by changing the ability of the stratum corneum to retain moisture, softening the skin, improving the skin's permeability, acting as penetration assistants or hair-follicle openers or changing the state of the skin including the boundary layer.
- Illustrative penetration enhancers include but are not limited to polyhydric alcohols such as dipropylene glycol, propylene glycol, and polyethylene glycol; oils such as olive oil, squalene, and lanolin; fatty ethers such as cetyl ether and oleyl ether; fatty acid esters such as isopropyl myristate; urea and urea derivatives such as allantoin which affect the ability of keratin to retain moisture; polar solvents such as dimethyidecylphosphoxide, methyloctylsulfoxide, dimethyllaurylamide, dodecylpyrrolidone, isosorbitol, dimethylacetonide, dimethylsulfoxide, decylmethylsulfoxide, and dimethylformamide which affect keratin permeability; salicylic acid which softens the keratin; amino acids which are penetration assistants; benzyl nicotinate which is a hair f
- polymer matrix and/or face adhesive may further comprise one or more various thickeners, fillers, and other additives or components known for use in transdermal drug delivery systems (e.g.
- the transdermal patch to further modify properties of the matrix or face adhesive, such as polyvinylpyrrolidone (PVP), crosslinked PVP (crospovidone), polyvinylpyrrolidone/vinylacetate copolymers (PVP/VA, copovidone), ethylene-vinyl acetate copolymers, cellulose derivatives, silica, and other components.
- the polymer matrix may comprise a humectant.
- Humectants suitable for use in transdermal drug delivery systems e.g. the transdermal patch
- the amount of humectant can be selected based on desired properties, such as an amount effective to impart desired physical properties, such as the adhesion properties of the polymer matrix, such as shear.
- a humectant is used in an amount up from about 3% to about 10% dry weight of the polymer matrix, including about 3%, about 5% or about 10% dry weight.
- the system may be of any shape or size suitable for continuous systemic application.
- the polymer matrices and face adhesive layers described herein may be prepared by methods known in the art, and formed into systems by methods known in the art. For example, the polymer matrix material can be applied to a backing layer and release liner by methods known in the art.
- the polymer matrix may be brought into contact with a support layer, such a releaser liner layer or backing layer, in any manner known to those of skill in the art. Such techniques include calender coating, hot melt coating, solution coating, etc.
- the face adhesive layer also may be formed on a release liner, and then applied to the polymer matrix layer, and then the systems can be formed into sizes and shapes suitable for use
- a polymer matrix can be prepared by blending the components of the polymer matrix, applying the matrix material to a support layer such as a backing layer or release liner, and removing any remaining solvents, and a face adhesive layer can be prepared similarly.
- An exemplary general method is as follows: Appropriate amounts of polymer(s), therapeutic agent(s), other component(s), and organic solvent(s) (for example toluene, or ethyl acetate and/or isopropyl alcohol) are combined and thoroughly mixed together in a vessel. The formulation is then transferred to a coating operation where it is coated onto a protective release liner at a controlled specified thickness. The coated product is then passed through an oven in order to drive off all volatile processing solvents. The dried product on the release liner is then joined to the backing material and wound into rolls for storage.
- organic solvent(s) for example toluene, or ethyl acetate and/or isopropyl alcohol
- a face adhesive solution containing the face adhesive in a suitable solvent may be coated onto a release liner and dried in a convection oven.
- the dried face adhesive on the release liner may be laminated with the prepared drug-in-adhesive polymer matrix (after removing its release liner) to form a laminate with a face adhesive.
- Appropriate size and shape “systems” are die-cut from the roll material and then pouched. Other manufacturing methods are known in the art that are suitable for making the systems described herein.
- Therapeutic Agents The continuous systemic delivery described herein can be used for formulating any therapeutic agent, such as any therapeutic agent known or determined to be therapeutically active upon continuous systemic delivery .
- the therapeutic agent is an agonist of D1-like family of dopamine receptors.
- dopamine receptors has its general meaning in the art and refers to a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5.
- the D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4 receptors are members of the D2-like family.
- the term “D1-like family of dopamine receptors” has its general meaning in the art and refers to the D1-like family receptors coupled to the G protein Gs ⁇ . Gs ⁇ subsequently activates adenylyl cyclase, increasing the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).
- the D1-like family of dopamine receptors consists of: - D1 is encoded by the Dopamine receptor D1 gene (DRD1).
- D5 Dopamine receptor D5 gene
- DRD1 Dopamine receptor D5 gene
- DR1 dopamine receptor type 1
- DR1 agonist refers to a natural or synthetic compound that has a biological effect to increase the activity and/or the expression of dopamine receptor type 1.
- D1BR dopamine receptor type 5
- DRD5 dopamine receptor type 5
- DR5 agonist refers to a natural or synthetic compound that has a biological effect to increase the activity and/or the expression of dopamine receptor type 5.
- therapeutic agents include but are not limited to A-86929, dihydrexidine, dinapsoline, dinoxyline, doxanthrine, SKF-81297, SKF-82958, SKF-38393, fenoldopam, 6-Br- APB, stepholidine, rotigotine,A-68930, A-77636, CY-208,243, SKF-89145, SKF-89626, 7,8- Dihydroxy-5-phenyl-octahydrobenzo[h]isoquinoline, cabergoline, pergolide terguride... apomorphine, adrogolide SKF-83959...
- the therapeutic agent is fenoldopam.
- the term "fenoldopam” has is general meaning in the rat and refers to a rapid- acting vasodilator having the following structure in the art:
- the term fenoldopam intends not only the basic form of fenoldopam but also pharmaceutically acceptable salt forms of fenoldopam, the R or S enantiomers of fenoldopam, either individually or as a racemic mixture, and to mixtures thereof.
- the term “fenoldopam therapy” intends all medical conditions for which fenoldopam is or will be indicated, including, without limitation, for the treatment of hypertension, congestive heart failure, and acute and chronic renal failure.
- the therapeutic agent is rotigotine.
- the term “rotigotine” has is general meaning in the rat is having the following structure in the art: Also provided are methods of effecting continuous systemic delivery of a therapeutic agent (i.e. D1-like family of dopamine receptors agonist), by applying a system as described herein to the skin or mucosa of a subject in need thereof.
- a therapeutic agent i.e. D1-like family of dopamine receptors agonist
- treatment or “treat” refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase "induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- loading regimen may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- the phrase "maintenance regimen” or “maintenance period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
- continuous therapy e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.
- intermittent therapy e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]
- the continuous systemic delivery is formulated to achieve sustained delivery of the therapeutic agent (e.g.
- the D1-like family of dopamine receptors agonist over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, or at least about 7 days, such as for 1, 2, 3, 4, 5, 6 or 7 days or longer if desired.
- the method is effective to achieve therapeutic levels of the therapeutic agent during the application period.
- the method is effective to achieve a flux decline of less than 30% over the application period.
- a "therapeutically effective amount” is meant a sufficient amount of D1-like family of dopamine receptors agonist for use in a method for the treatment of ADPKD at a reasonable benefit/risk ratio applicable to any medical treatment.
- the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the age, body weight, general health, sex and diet of the subject; the time of administration and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well known within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the daily dosage of D1-like family of dopamine receptors agonist may be varied over a wide range from 0.01 to 5,000 mg per adult per day.
- the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the D1-like family of dopamine receptors agonist for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, typically from 1 mg to about 100 mg of the active ingredient.
- an effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
- the person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- the administration by transdermal patch is at a daily dosage of D1-like family of dopamine receptors agonist which may be varied over a wide range from 1 à 20 mg/cm 2 per adult per day.
- ADPKD patients receive the D1-like family of dopamine receptors agonist using the continuous systemic delivery (e.g transdermal patch or pump) at the dose of 1, 2, 3, 4 or 5 mg per day.
- the D1-like family of dopamine receptors agonist as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
- pharmaceutically acceptable excipients such as a carboxylate, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, colophony, colophony, colophony, colophony, colophony, colophony, colophony, colophony, colophony, colophony, colophonyl, colophonyl, colophonyl, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol,
- ADPKD autosomal dominant polycystic kidney disease
- Endothelium-dependent flow-mediated dilatation of the radial artery assessed by echotracking coupled to Doppler (A), and nitric oxide (NO) release, estimated by the measurement of the NO metabolite nitrite by a chemiluminescent-based assay (B), in response to hand skin heating, aortic pulse pressure (C) did not change during follow-up in non-treated ADPKD patients.
- flow-mediated dilatation increased in patients treated with 4-mg rotigotine and this was associated with an increase in NO release after 8 weeks of treatment.
- FIG. 2 To specifically assess the role of endothelial polycystin independently from the non- specific consequences of the kidney disease C57/Bl6J mouse transgenic models with an endothelial cell-specific inducible knockout of Pkd1 (VE-Cadh/Pkd1fl/fll) have been developed. Compared to control mice with maintained endothelial expression of polycystin-1 (Pkd1fl/fl), VE-Cadh/Pkd1fl/fl had a decreased mesenteric artery endothelium-dependent dilatation in response to stepwise increase in flow assessed by arteriography (A) and an increased blood pressure measured by tail-cuff plethysmography (B).
- A arteriography
- B tail-cuff plethysmography
- Figure 3 Representative scanning electron micrographs of the endothelial surface of the length of the endothelial protrusions, including microvilli and primary cilia obtained in Pkd1 lox/lox , iCdh5-cre/ERT2-Pkd1 del/del mice receiving or not fenoldopam (4 ⁇ g/kg/h) during 4 weeks. Group effect was determined by one-way ANOVA followed by Bonferroni's post hoc test.
- ADPKD advanced protein kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinastolic blood pressure (BP) ⁇ 140/90 mmHg] and a glomerular filtration rate (GFR), determined by CKD-EPI formula, >45 ml/min/1.73 m 2 were included.
- HTN hypoxia filtration rate
- GFR glomerular filtration rate
- Radial artery waveforms of the same arm were recorded non-invasively by applanation tonometry and analyzed by using a dedicated software (Sphygmocor, Atcor Medical), allowing to calculate an averaged radial artery waveform and derive a corresponding central aortic pressure waveform using a validated generalized transfer function.
- 24 Aortic pressure waveforms were subjected to further analysis by the Sphygmocor software to identify the time to the shoulder of the first and second pressure wave components during systole.
- the pressure at the shoulder of the first component was identified as P1 height (forward pressure wave), and the pressure difference between this point and the maximal pressure during systole (augmentation: ⁇ P) was identified as the reflected pressure wave.
- PP pulse pressure
- carotid-femoral pulse wave velocity, indicator of aortic stiffness was assessed (Sphygmocor).
- the distal skin heating procedure was performed by introducing the right hand in a water-filled thermocontrolled tank. 13 The device was then filled with water and the temperature was fixed to 34°C for 20 min to establish baseline conditions. Then, hand skin heating was performed by gradually increasing the water temperature from 34°C to 44°C, with each level of temperature maintained for 7 min.
- Radial artery diameter and blood flow were measured during the last minute of each step by high-resolution echotracking coupled to a Doppler system (Artlab System, Esaote).
- the radial artery endothelium-independent dilatation was assessed using 0.3 mg of sublingual glyceryl trinitrate.
- Blood samples were drawn at 34°C for standard biochemistry analyses and the determination of total blood viscosity using a cone-plate viscometer (Ex100 CTB, Brookfield).
- EETs epoxyeicosatrienoic acids
- DHETs dihydroxyecosatrienoic acids
- MCP-1 monocyte chemoattractant protein-1
- a maximal number of ADPKD patients to include was fixed to 10 per group based on a trial exit rate not greater than 20%, which is the average rate of trial exits due to adverse events related to 1-year treatment with low-dose rotigotine in patients with restless legs syndrome. 27,28 Analysis Analyses were performed using the R software (version 4.0.5 et version 1.1.463 of RStudio). Continuous variables are presented as mean ⁇ SD in the text, unless differently indicated. Qualitative variables are presented as absolute and relative frequencies. Baseline demographic and clinical data were analyzed using a non-parametric Kruskal-Wallis test, followed by a Dunn test in case of significance, and Fisher’s exact tests as appropriate.
- Endothelial-specific knock-out of Pkd1 was generated using a tamoxifen inducible cre-loxP recombination system, on a C57BL/6J genetic background as previously described 29 . Homozygous iCdh5-cre/ERT2-Pkd1 del/del and control Pkd1 lox/lox male mice, all identically exposed to tamoxifen, were used.
- Acute effect of fenoldopam The mesenteric artery relaxation to the peripheral DR agonist fenoldopam (Sigma SM20198) was studied using a small vessel myograph 29 , before and after addition of the specific antagonist of the DR5 receptor LE-PM436 29 in iCdh5-cre/ERT2-Pkd1 del/del and Pkd1 lox/lox mice.
- the impact of chronic kidney disease induced by subtotal nephrectomy 29 on fenoldopam-induced relaxation was studied in iCdh5-cre/ERT2-Pkd1 del/del mice. Briefly, after sacrifice, the mesentery was removed and placed in cold oxygenated Krebs buffer.
- a 1.5-2.0 mm segment of first order of mesenteric resistance artery segment was mounted on a myograph (DMT, Aarhus). After normalization, relaxation to fenoldopam (10 -9 to 10 -5 M) was evaluated in segments precontracted with phenylephrine (Phe: 10 -5 M). Furthermore, the impact of 30- min pretreatment with fenoldopam (10 -6 M) on mesenteric artery FMD was studied in iCdh5- cre/ERT2-Pkd1 del/del . For this, a 2-3 mm segment of third mesenteric resistance artery segment was mounted on an arteriograph (DMT).
- DMT arteriograph
- mice were perfused with a solution of paraformaldehyde 4%, glutaraldehyde 0.5% and HEPES buffer (Sigma) 0.2 mM pH 7.4. Segments of the aortic arch were dissected and fixed overnight in glutaraldehyde 2.5% + HEPES 0.2 mM pH 7.4 + lanthanum 2% (Sigma). The samples were thereafter fixed 1h in OSO4 1% (EMS) at 4°C. Dehydration was performed by graded series of ethanol.
- EXAMPLE 1 Introduction Preliminary results obtained using acute local infusion of dopamine (Lorthioir et al, Kidney International 2014) suggested that stimulating peripheral dopaminergic receptors may prevent the alteration in vascular function of patients with autosomal dominant polycystic kidney disease (ADPKD).
- ADPKD autosomal dominant polycystic kidney disease
- ADPKD autosomal dominant polycystic kidney disease
- EXAMPLE 2 Introduction Preliminary results obtained using acute local infusion of dopamine (Lorthioir et al, Kidney International 2014) suggested that stimulating peripheral dopaminergic receptors may prevent the alteration in vascular function of patients with autosomal dominant polycystic kidney disease (ADPKD). The aim of this experimental study was to assess the interest of the chronic stimulation of dopaminergic receptor stimulation independently from non-specific consequences of this approach on kidney disease.
- ADPKD autosomal dominant polycystic kidney disease
- mice with endothelial deletion of polycystin-1 had a decreased endothelium-dependent dilatation and an increased blood pressure.
- the administration of fenoldopam allowed to improve endothelium-dependent dilatation and to normalize blood pressure in mice with endothelial deletion of polycystin-1.
- EXAMPLE 3 Chronic effect of fenoldopam Scanning electron microscopy analysis revealed the presence of protrusions at the endothelial cell surface of the aortic arch of control mice that were mainly located in specific regions thought to be dependent of a high level shear stress (Data not shown). It was not possible to formally discriminate microvilli from primary cilia but, as previously described, 14 microvilli seemed to predominate. Endothelial polycystin-1-deficient mice exhibited protrusions that were characterized by a stockier and more compact aspect compared to the control mice.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease affecting 1 in 1,000 to 1 in 2,500 individuals worldwide. The inventor's study performed in 6 patients with ADPKD supports the hypothesis that the stimulation of the dopaminergic system, in particular D1-like family of dopamine receptors, may improve endothelial function by restoring cilia length and mechanotransductory capacity. The inventors carefully assess whether the deficiency in endothelial polycystin-1 and cilia promotes or potentiates both cardiovascular and renal alterations, to explore the mechanisms involved, and to propose and test new pharmacological approaches, in particular targeting the dopaminergic system, to prevent complications of ADPKD. The present invention relates to a method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a D1-like family of dopamine receptors agonist through a continuous systemic delivery.
Description
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FIELD OF THE INVENTION: The present invention is in the field of kidney disease. The present invention relates to methods and pharmaceutical compositions for the treatment of autosomal dominant polycystic kidney disease using a D1-like family of dopamine receptors agonist through a continuous systemic delivery. BACKGROUND OF THE INVENTION: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease affecting 1 in 1,000 to 1 in 2,500 individuals worldwide. ADPKD patients present a progressive impairment of kidney function related to the development of multiple renal cysts, typically leading to end- stage renal disease around the age of 55 to 65 years. Irrespective of decreased kidney function, ADPKD is also characterized by an increase in cardiovascular diseases. In particular, ADPKD patients develop arterial hypertension at an early stage of the disease, as well as various left ventricular hypertrophy, cardiac valvulopathies, intracranial aneurysms, and aortic dissections (1,2). In addition, patients with ADPKD display an altered cardiovascular adaptation to exercise (3) and also after surgical creation of arterio-venous fistula (AVF) as a native vascular access for hemodialysis in end-stage renal disease (4). Genetic mutations in polycystin 1 (PKD1) are responsible for the majority of resolved cases of ADPKD (approximately 85%, >2000 pathogenic mutations described in the ADPKD mutation database [http://pkdb.mayo.edu]), with Polycystin-2 (PKD2) (10%) and to a lesser extent GANAB and DNAJB11 mutations. PKD1 and PKD2 respectively encode polycystin-1 and polycystin-2. Polycystin-1 is a transmembrane protein with a large extracellular domain acting as a sensor of mechanical stimuli, with an intracellular domain that interacts with the transient receptor potential channel polycystin-2 (TRPP2), assembled at the membrane in a 1:3 ratio (5). These proteins form a complex at the primary cilium of renal epithelial cells, sensing flow variation and promoting calcium entry to control cell function and proliferation. The alteration in this pathway contributes to promote cystogenesis in ADPKD patients (6). Moreover, increasing evidence suggests that the cardiovascular complications of ADPKD are a direct consequence of the presence of abnormal polycystins in vascular cells (7, 8, 9). In particular,
calcium-dependent endothelial NO-synthase activation in response to fluid shear stress is abolished in polycystin-1 or polycystin-2 deficient endothelial cells. The inventors confirmed this finding in vivo in humans by demonstrating that the endothelium-dependent flow-mediated dilatation during sustained flow conditions is profoundly reduced in ADPKD patients, due to the complete loss of NO synthesis (10). Restoring the function of the vascular endothelium may thus represent a unique opportunity to prevent the complications of ADPKD. In this context, the inventors assess the impact of chronic administration of rotigotine on endothelial function, peripheral and central hemodynamics in ADPKD patients and to obtain specific mechanistic insights by analyzing endothelial Pkd1-deficient mice. SUMMARY OF THE INVENTION: The present invention relates to the use of a continuous systemic delivery of D1-like family of dopamine receptors agonist for the treatment of autosomal dominant polycystic kidney disease (ADPKD). In particular, the present invention is defined by the claims. DETAILED DESCRIPTION OF THE INVENTION: Altered polycystin-mediated endothelial flow mechanosensitivity contributes to the development of hypertension and cardiovascular complications in patients with autosomal dominant polycystic kidney disease (ADPKD). Stimulation of endothelial type 5 dopamine receptors (DR5) can acutely compensate for the endothelial consequences of polycystin deficiency, but the chronic impact of this approach has to be evaluated in ADPKD. The inventor’s study performed in patients with ADPKD supports the hypothesis that the stimulation of the dopaminergic system, in particular D1-like family of dopamine receptors, may improve endothelial function by restoring cilia length and mechanotransductory capacity (10). In this context, the inventors carefully assess whether the deficiency in endothelial polycystin-1 and cilia promotes or potentiates both cardiovascular and renal alterations, to explore the mechanisms involved, and to propose and test new pharmacological approaches, in particular targeting the dopaminergic system, to prevent complications of ADPKD. Indeed, the inventors demonstrate that in ADPKD patients chronic administration of rotigotine improves conduit artery endothelial function through the restoration of flow-induced NO release as well as hemodynamics, and confirms that endothelial DR5 activation represents a promising pharmacological approach to prevent cardiovascular complications of ADPKD.
Accordingly, the first object of the present invention relates to a method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a D1-like family of dopamine receptors agonist through a continuous systemic delivery. As used herein, the term “subject” denotes a mammal, such as a rodent, a feline, a canine, and a primate. Particularly, the subject according to the invention is a human. More particularly, the subject according to the invention has or is susceptible to have kidney disease, in particular ADPKD. As used herein, the term “subject” encompasses “patient” As used herein, the term “autosomal dominant polycystic kidney disease” (ADPKD) has its general meaning in the art and refers to an inherited condition that causes small fluid-filled sacs called cysts to develop in the kidneys. ADPKD is caused by a genetic fault that disrupts the normal development of some of the cells in the kidneys and causes cysts to grow. The affected genes in ADPKD are: polycystin 1 (PKD1), which accounts for 85% of cases polycystin 2 (PKD2) which accounts for 15% of cases. PKD1, which is the protein encoded by the PKD1 gene, is present on the cilia and is thought to sense the flow with its large extracellular domains, activating the calcium channels associated with PKD2, the product of gene PKD2, as a result of the genetic setting of ADPKD as explained in the genetics sub-section above. The different symptoms and signs are, but are not limited to acute loin pain, blood in the urine, ballotable kidneys, subarachnoid hemorrhage (berry aneurysm), hypertension, associated liver cysts, uremia due to kidney failure, anemia due to chronic kidney disease, increase RBC or erythropoietin secretion. As used herein, “continuous systemic delivery” means the administration continuous of a drug product systemically in the body of the patient. Continuous systemic delivery is preferred in order to achieve prolonged and relatively uniform blood concentrations of the drug. As used herein, “flux” (also called “permeation rate”) is defined as the absorption of a drug through skin or mucosal tissue, and is described by Fick's first law of diffusion: J=−D(dCm/dx)
where J is the flux in g/cm2/sec, D is the diffusion coefficient of the drug through the skin or mucosa in cm2/sec and dCm/dx is the concentration gradient of the drug across the skin or mucosa. In some embodiment, the continuous systemic delivery is administered with a pump. In some embodiment, the D1-like family of dopamine receptors agonist is typically administered via a pump (e.g. a portable infusion pump) that delivers D1-like family of dopamine receptors agonist boluses at specific intervals. Other suitable pumps are e.g. disclosed in the international patent application published under reference WO2007041386 or in U.S. Patents Nos.4,722,734; 5,013,293; 5,312,325; 5,328,454; 5,336,168; and 5,372,579. As used herein, the term “pump” is intended to include any number of drug delivery systems which are capable of dispensing a fluid to a user upon activation. Such drug delivery systems include, for example, injection systems, infusion pumps, bolus injectors, and the like. Drug pump is configured such that, upon activation by a user by depression of the activation mechanism, the drug pump is initiated to: insert a fluid pathway into the user; enable, connect, or open necessary connections between a drug container, a fluid pathway, and a sterile fluid conduit; and force drug fluid stored in the drug container through the fluid pathway and fluid conduit for delivery into a user. One or more optional safety mechanisms may be utilized, for example, to prevent premature activation of the drug pump. The drug pump is capable of delivering a range of drugs with different viscosities and volumes. The drug pump is capable of delivering a drug at a controlled flow rate (speed) and/or of a specified volume. In one embodiment, the drug delivery process is controlled by one or more flow restrictors within the fluid pathway connection and/or the sterile fluid conduit. In other embodiments, other flow rates may be provided by varying the geometry of the fluid flow path or delivery conduit, varying the speed at which a component of the drive mechanism advances into the drug container to dispense the drug therein, or combinations thereof. In some embodiment, the pump is an osmotic pump.
As used herein, the term “osmotic pump” relate to miniature infusion pumps for the continuous dosing of laboratory animals. These minipumps provide researchers with a method for controlled and continuous agent delivery in vivo. Osmotic pumps can be used for systemic administration when implanted subcutaneously or intraperitoneally. They can be attached to a catheter to provide targeted delivery for intravenous, intraarterial, intracerebral, or cranial/calvarial infusion. The pumps can be used to target delivery to a variety of sites including direct substance administration to cord, spleen, liver, organ or tissue transplants. A single pump may provide up to four weeks of infusion. As used herein, “needle” is intended to refer to a variety of needles including but not limited to conventional hollow needles, such as a rigid hollow steel needles, and solid core needles more commonly referred to as a “trocars.” In a preferred embodiment, the needle is a gauge solid core trocar and in other embodiments, the needle may be any size needle suitable to insert the cannula for the type of drug and drug administration (e.g., subcutaneous, intramuscular, intradermal, etc.) intended. A sterile boot may be utilized within the needle insertion mechanism. The sterile boot is a collapsible sterile membrane that is in fixed engagement at a proximal end with the manifold and at a distal end with the base. In at least on embodiment, the sterile boot is maintained in fixed engagement at a distal end between base and insertion mechanism housing. Base includes a base opening through which the needle and cannula may pass-through during operation of the insertion mechanism, as will be described further below. Sterility of the cannula and needle are maintained by their initial positioning within the sterile portions of the insertion mechanism. Specifically, as described above, needle and cannula are maintained in the sterile environment of the manifold and sterile boot. In some embodiment, the continuous systemic delivery is administered with a transdermal drug delivery system. As used herein, the term “transdermal” refers to delivery, administration or application of a drug by means of direct contact with skin or mucosa. Such delivery, administration or application is also known as dermal, percutaneous, transmucosal and buccal. As used herein, “dermal” includes skin and mucosa, which includes oral, buccal, nasal, rectal and vaginal mucosa.
As used herein, the term “transdermal drug delivery system” refers to a system (e.g., a device) comprising a composition that releases drug upon application to the skin (or any other surface noted above). Thereafter, the drug is dispersed throughout the patient's body by blood circulation. Typically, the transdermal drug delivery system is a substantially non-aqueous, solid form, capable of conforming to the surface with which it comes into contact, and capable of maintaining such contact so as to facilitate topical application without adverse physiological response, and without being appreciably decomposed by aqueous contact during topical application to a subject. Many such systems are known in the art and commercially available, such as transdermal drug delivery patches. In accordance with specific embodiments described herein, the transdermal drug delivery systems comprise a drug-containing polymer matrix that comprises a pressure-sensitive adhesive or bioadhesive and drug, and a face adhesive layer disposed on the skin-contacting side of the drug-containing polymer matrix that is adopted for application to a user's (e.g., a subject's) skin. In one embodiment, the transdermal drug delivery system is a transdermal patch. As used herein, “polymer matrix” refers to a polymer composition which contains one or more drugs. In some embodiments, the matrix comprises a pressure-sensitive adhesive polymer or a bioadhesive polymer. In one embodiment, the transdermal drug delivery system, (e.g. the transdermal patch) consists of a backing layer, a single drug-containing polymer matrix layer, a single face adhesive layer, and, optionally, a release liner that is removed prior to use. The transdermal drug delivery system (e.g. the transdermal patch) may be packaged or provided in a package, typically a peelable pouch, as is used in the art for transdermal drug delivery systems in general. A wide variety of materials known to those skilled in the art of transdermal drug delivery may be used as pouchstock materials, including Surlyn® packaging resins (ethylene acid copolymers) sold by DuPont®, Wilmington, Del. Face Adhesive The transdermal drug delivery system (e.g. the transdermal patch) described herein may comprise a skin-contacting face adhesive layer, separate from the drug-containing polymer matrix. In some embodiments, the face adhesive comprises a rubber-based polymer, such as a
rubber-based pressure sensitive adhesive, such as a polyisobutylene or styrene-isoprene-styrene polymer, optionally formulated with a tackifier or plasticizer to provide pressure-sensitive adhesive properties. Examples of suitable rubber-based polymers and rubber-based pressure-sensitive adhesives include natural or synthetic polyisoprene, polybutylene, polyisobutylene, styrene-butadiene polymers, styrene-isoprene-styrene block copolymers, hydrocarbon polymers, such as butyl rubber, halogen-containing polymers, such as polyacrylic-nitrile, polytetrafluoroethylene, polyvinylchloride, polyvinylidene chloride, and polychlorodiene, and other copolymers thereof. Further specific examples include polyisobutylene pressure-sensitive adhesive polymers, such as DURO-TAK® 87-6908 (Henkel), which comprises polyisobutylene polymer and tackifier. Other specific examples include styrene-isoprene-styrene block copolymers, such as Kraton® D1111 KT (Kraton Performance Polymers, Inc.). The face adhesive layer may comprise a single rubber-based pressure-sensitive adhesive, or a blend of two or more adhesives. The face adhesive layer may comprise one or more tackifiers, plasticizing agents (such as mineral oil, hydrogenated hydrocarbon resins, aliphatic resins, rosins, and terpenes), and/or other components selected to confer satisfactory physical stability, chemical stability, and/or skin adhesion, as discussed in more detail below. The face adhesive layer may comprise at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% by dry weight of the one or more rubber-based pressure sensitive adhesives. In this context, “% by dry weight of the one or more rubber-based pressure sensitive adhesives” includes the dry weight of the rubber-based polymer and any tackifiers and/or plasticizers included in the composition. The face adhesive layer may be applied at a coat weight of from 2 to about 20 mg/cm2, including at from about 5 to about 10 mg/cm2, including 5 mg/cm2, 6 mg/cm2, 7 mg/cm2, 8 mg/cm2, 9 mg/cm2, or 10 mg/cm2, or any coat weight there between. As used herein, “coat weight” refers to the weight of the layer at issue per unit area of the active surface area of the transdermal drug delivery system (e.g. the transdermal patch). Drug-Containing Polymer Matrix
The compositions described herein comprise a polymer matrix that is suitable for use with the therapeutic agent (e.g. the D1-like family receptor agonist) being formulated. Typical polymers used in a polymer matrix for a transdermal drug delivery system (e.g. the transdermal patch) include pressure-sensitive adhesive acrylic polymers, silicone-containing polymers, and rubber-based polymers (such as polyisobutylene and styrene-isoprene-styrene polymers). Non- limiting examples of suitable polymers are set forth below. The term “acrylic polymer” is used here as in the art interchangeably with “polyacrylate” “polyacrylic polymer” and “acrylic adhesive”. Suitable acrylic-based polymers include homopolymers, copolymers, terpolymers, and the like of various acrylic acids or esters. In some embodiments, acrylic-based polymers are adhesive polymers. In other embodiments, acrylic- based polymers function as an adhesive by the addition of tackifiers, plasticizers, crosslinking agents or other additives. Often, acrylic polymers used in transdermal drug delivery systems (e.g. the transdermal patch) include polymers of one or more monomers of acrylic acids and other copolymerizable monomers, copolymers of alkyl acrylates and/or methacrylates and/or copolymerizable secondary monomers or monomers with functional groups, and combinations of acrylic-based polymers based on their functional groups. Acrylic-based polymers having functional groups include copolymers and terpolymers which contain, in addition to nonfunctional monomer units, further monomer units having free functional groups, where the monomers can be monofunctional or polyfunctional. By varying the amount of each type of monomer added, the cohesive properties of the resulting acrylic polymer can be changed as is known in the art. In some embodiments, the acrylic polymer is composed of at least 50% by weight of an acrylate or alkyl acrylate monomer, from 0 to 20% of a functional monomer copolymerizable with the acrylate, and from 0 to 40% of other monomers. Typical acrylate monomers include acrylic acid and methacrylic acid and alkyl acrylic or methacrylic esters such as methyl acrylate, ethyl acrylate, propyl acrylate, amyl acrylate, butyl acrylate, butyl methacrylate, hexyl acrylate, methyl methacrylate, hexyl methacrylate, heptyl acrylate, octyl acrylate, nonyl acrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylate, glycidyl acrylate, and corresponding methacrylic esters.
Typical non-functional acrylic-based polymers include any acrylic based polymer having no or substantially no free functional groups. As used herein, “functional monomers or groups” are monomer units typically in acrylic- based polymers which have reactive chemical groups which modify the acrylic-based polymers directly or which provide sites for further reactions. Examples of functional groups include carboxyl, epoxy, hydroxyl, sulfoxyl, and amino groups. Acrylic-based polymers having functional groups contain, in addition to the nonfunctional monomer units described above, further monomer units having free functional groups. As noted above, the monomers can be monofunctional or polyfunctional. Typical carboxyl functional monomers include acrylic acid, methacrylic acid, itaconic acid, maleic acid, and crotonic acid. Typical hydroxyl functional monomers include 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate, hydroxymethyl acrylate, hydroxymethyl methacrylate, hydroxyethyl acrylate, hydroxyethyl methacrylate, hydroxypropyl acrylate, hydroxypropyl methacrylate, hydroxybutyl acrylate, hydroxybutyl methacrylate, hydroxyamyl acrylate, hydroxyamyl methacrylate, hydroxyhexyl acrylate, hydroxyhexyl methacrylate. Others include amide-group containing-monomers such as octyl acrylamide, and vinyl group containing monomers, such as vinyl acetate and vinyl pyrrolidone In some embodiments, the functionality of the polymer(s) is selected depending on the drug being formulated, e.g., is selected based on whether the functional group is reactive or non- reactive with a functional group on the drug being formulated. Suitable acrylic polymers also include pressure-sensitive adhesives which are commercially available, such as the acrylic-based adhesives sold under the trademarks DURO-TAK® and GELVA® by Henkel Corporation, Bridgewater, N.J. (such as DURO-TAK® 87-2516, -2287, -4287, -4098, -2852, -2196, -2296, -2194, -2516, -2070, -2353, -2154, -2510, -9085, -9088 and 73-9301; and GELVA® 2480, 788, 737, 263, 1430, 1753, 1151, 2450, 2495, 3067, 3071, 3087 and 3235). Other suitable acrylic adhesives include those sold under the trademark EUDRAGIT® by Evonik Industries AG, Essen Germany. For example, hydroxy functional adhesives with a reactive functional OH group can be used, including GELVA® 737, 788, and 1151, and DURO-TAK® 87-2287, -4287, -2510 and -2516. In some embodiments, the drug-containing polymer matrix comprises a silicone-based polymer. The term “silicone-based” polymer is used interchangeably with the terms silicon polymers, siloxane, polysiloxane, and silicones as used herein and as known in the art. A
suitable silicone-based polymer may also be a pressure-sensitive adhesive. Thus, in some embodiments, the silicone-based polymer is an adhesive polymer. In other embodiments, the silicone-based polymer functions as an adhesive by the addition of tackifiers, plasticizers, crosslinking agents, or other additives. Suitable polysiloxanes include silicone pressure-sensitive adhesives which are based on two major components: (i) a polymer or gum and (ii) a tackifying resin. A polysiloxane adhesive can be prepared by cross-linking a gum, typically a high molecular weight polydiorganosiloxane, with a resin, to produce a three-dimensional silicate structure, via a condensation reaction in an appropriate organic, volatile solvent, such as ethyl acetate or heptane. The ratio of resin to polymer can be adjusted in order to modify the physical properties of polysiloxane adhesives. Sobieski, et al., “Silicone Pressure Sensitive Adhesives,” Handbook of Pressure-Sensitive Adhesive Technology, 2nd ed., pp.508-517 (D. Satas, ed.), Van Nostrand Reinhold, New York (1989). Exemplary silicone-based polymers are adhesives (e.g., capable of sticking to the site of topical application), including pressure-sensitive adhesives. Illustrative examples of silicone-based polymers having reduced silanol concentrations include silicone-based adhesives (and capped polysiloxane adhesives) such as those described in U.S. Pat. No. Re.35,474 and U.S. Pat. No. 6,337,086, which are incorporated herein by reference in their entireties, and which are commercially available from Dow Corning Corporation (Dow Corning Corporation, Medical Products, Midland, Mich.) as BIO-PSA® 7-4100, -4200 and -4300 product series, and non- sensitizing, pressure-sensitive adhesives produced with compatible organic volatile solvents (such as ethyl acetate or heptane) and available commercially under their BIO-PSA® 7-4400 series, -4500 series, such as -4502, and -4600 series. As noted above, in some embodiments the drug-containing polymer matrix comprises one or more rubber-based polymers, such as one or more rubber-based pressure-sensitive adhesives, such as any one or more of those discussed above in the context of the face adhesive. In accordance with any of the embodiments described herein, the polymer matrix and/or face adhesive layer may comprise an antioxidant. The antioxidant may be one known for use in transdermal drug delivery systems (e.g. the transdermal patch), such as butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tertiary-butylhydroquinone (TBHQ), ascorbic acid,
ascorbyl palmitate, alpha-tocopherol and its esters, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfite, and propyl gallate, and mixtures thereof. The antioxidant may comprise from about 0 to about 1%, including from about 0 to about 0.5% by weight of the polymer matrix face adhesive laye In accordance with any of the embodiments described herein, the polymer matrix and/or face adhesive polymer may comprise one or more other pharmaceutically acceptable excipients, such as a plasticizer, penetration enhancer, filler, and the like. In some embodiments, the polymer matrix comprises from about 0% to about 20% of one or more such excipients. A “penetration enhancer” is an agent known to accelerate the delivery of the drug through the skin. These agents also have been referred to as accelerants, adjuvants, and sorption promoters, and are collectively referred to herein as “enhancers.” This class of agents includes those with diverse mechanisms of action, including those which have the function of improving percutaneous absorption, for example, by changing the ability of the stratum corneum to retain moisture, softening the skin, improving the skin's permeability, acting as penetration assistants or hair-follicle openers or changing the state of the skin including the boundary layer. Illustrative penetration enhancers include but are not limited to polyhydric alcohols such as dipropylene glycol, propylene glycol, and polyethylene glycol; oils such as olive oil, squalene, and lanolin; fatty ethers such as cetyl ether and oleyl ether; fatty acid esters such as isopropyl myristate; urea and urea derivatives such as allantoin which affect the ability of keratin to retain moisture; polar solvents such as dimethyidecylphosphoxide, methyloctylsulfoxide, dimethyllaurylamide, dodecylpyrrolidone, isosorbitol, dimethylacetonide, dimethylsulfoxide, decylmethylsulfoxide, and dimethylformamide which affect keratin permeability; salicylic acid which softens the keratin; amino acids which are penetration assistants; benzyl nicotinate which is a hair follicle opener; and higher molecular weight aliphatic surfactants such as lauryl sulfate salts which change the surface state of the skin and drugs administered. Other agents include oleic and linoleic acids, ascorbic acid, panthenol, butylated hydroxytoluene (BHT), tocopherol, tocopheryl acetate, tocopheryl linoleate, propyl oleate, and isopropyl palmitate. In accordance with any of the embodiments described herein, the polymer matrix and/or face adhesive may further comprise one or more various thickeners, fillers, and other additives or components known for use in transdermal drug delivery systems (e.g. the transdermal patch) to
further modify properties of the matrix or face adhesive, such as polyvinylpyrrolidone (PVP), crosslinked PVP (crospovidone), polyvinylpyrrolidone/vinylacetate copolymers (PVP/VA, copovidone), ethylene-vinyl acetate copolymers, cellulose derivatives, silica, and other components. In accordance with any of the embodiments described herein, the polymer matrix may comprise a humectant. Humectants suitable for use in transdermal drug delivery systems (e.g. the transdermal patch) are known, and include PVP, crospovidone, copovidone, and combinations of any two or more thereof. The amount of humectant can be selected based on desired properties, such as an amount effective to impart desired physical properties, such as the adhesion properties of the polymer matrix, such as shear. In some embodiments, a humectant is used in an amount up from about 3% to about 10% dry weight of the polymer matrix, including about 3%, about 5% or about 10% dry weight. The system may be of any shape or size suitable for continuous systemic application. The polymer matrices and face adhesive layers described herein may be prepared by methods known in the art, and formed into systems by methods known in the art. For example, the polymer matrix material can be applied to a backing layer and release liner by methods known in the art. For example, after the polymer matrix is formed, it may be brought into contact with a support layer, such a releaser liner layer or backing layer, in any manner known to those of skill in the art. Such techniques include calender coating, hot melt coating, solution coating, etc. The face adhesive layer also may be formed on a release liner, and then applied to the polymer matrix layer, and then the systems can be formed into sizes and shapes suitable for use For example, a polymer matrix can be prepared by blending the components of the polymer matrix, applying the matrix material to a support layer such as a backing layer or release liner, and removing any remaining solvents, and a face adhesive layer can be prepared similarly. The order of steps, amount of ingredients, and the amount and time of agitation or mixing can be determined and optimized by the skilled practitioner. An exemplary general method is as follows: Appropriate amounts of polymer(s), therapeutic agent(s), other component(s), and organic solvent(s) (for example toluene, or ethyl acetate and/or isopropyl alcohol) are combined and
thoroughly mixed together in a vessel. The formulation is then transferred to a coating operation where it is coated onto a protective release liner at a controlled specified thickness. The coated product is then passed through an oven in order to drive off all volatile processing solvents. The dried product on the release liner is then joined to the backing material and wound into rolls for storage. A face adhesive solution containing the face adhesive in a suitable solvent may be coated onto a release liner and dried in a convection oven. The dried face adhesive on the release liner may be laminated with the prepared drug-in-adhesive polymer matrix (after removing its release liner) to form a laminate with a face adhesive. Appropriate size and shape “systems” are die-cut from the roll material and then pouched. Other manufacturing methods are known in the art that are suitable for making the systems described herein. Therapeutic Agents The continuous systemic delivery described herein can be used for formulating any therapeutic agent, such as any therapeutic agent known or determined to be therapeutically active upon continuous systemic delivery . In particular, the therapeutic agent is an agonist of D1-like family of dopamine receptors. As used herein, the term “dopamine receptors” has its general meaning in the art and refers to a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4 receptors are members of the D2-like family. As used herein, the term “D1-like family of dopamine receptors” has its general meaning in the art and refers to the D1-like family receptors coupled to the G protein Gsα. Gsα subsequently activates adenylyl cyclase, increasing the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). The D1-like family of dopamine receptors consists of: - D1 is encoded by the Dopamine receptor D1 gene (DRD1). - D5 is encoded by the Dopamine receptor D5 gene (DRD5).
As used herein, the term “dopamine receptor type 1” (DR1), also known as DRD1, has its general meaning in the art and refers to a protein that in humans is encoded by the DRD1 gene. The naturally occurring human DR1 protein has an amino acid sequence as shown in NCBI accession number: NP_000785. As used herein, the term “dopamine receptor type 1 (DR1) agonist” refers to a natural or synthetic compound that has a biological effect to increase the activity and/or the expression of dopamine receptor type 1. As used herein, the term “dopamine receptor type 5” (DR5), also known as D1BR or DRD5, has its general meaning in the art and refers to a protein that in humans is encoded by the DRD5 gene. The naturally occurring human DR5 protein has an amino acid sequence as shown in NCBI accession number: NP_000789.1. As used herein, the term “dopamine receptor type 5 (DR5) agonist” refers to a natural or synthetic compound that has a biological effect to increase the activity and/or the expression of dopamine receptor type 5. Examples of therapeutic agents include but are not limited to A-86929, dihydrexidine, dinapsoline, dinoxyline, doxanthrine, SKF-81297, SKF-82958, SKF-38393, fenoldopam, 6-Br- APB, stepholidine, rotigotine,A-68930, A-77636, CY-208,243, SKF-89145, SKF-89626, 7,8- Dihydroxy-5-phenyl-octahydrobenzo[h]isoquinoline, cabergoline, pergolide terguride… apomorphine, adrogolide SKF-83959… In some embodiment, the therapeutic agent is fenoldopam. As used herein, the term "fenoldopam" has is general meaning in the rat and refers to a rapid- acting vasodilator having the following structure in the art:
The term fenoldopam intends not only the basic form of fenoldopam but also pharmaceutically acceptable salt forms of fenoldopam, the R or S enantiomers of fenoldopam, either individually or as a racemic mixture, and to mixtures thereof. As used herein, the term "fenoldopam therapy" intends all medical conditions for which fenoldopam is or will be indicated, including, without limitation, for the treatment of hypertension, congestive heart failure, and acute and chronic renal failure. In some embodiment, the therapeutic agent is rotigotine. As used herein, the term “rotigotine” has is general meaning in the rat is having the following structure in the art:
Also provided are methods of effecting continuous systemic delivery of a therapeutic agent (i.e. D1-like family of dopamine receptors agonist), by applying a system as described herein to the skin or mucosa of a subject in need thereof.
As used herein, the term "treatment" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]). In some embodiments, the continuous systemic delivery is formulated to achieve sustained delivery of the therapeutic agent (e.g. the D1-like family of dopamine receptors agonist) over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, or at least about 7 days, such as for 1, 2, 3, 4, 5, 6 or 7 days or longer if desired. In some embodiments, the method is effective to achieve therapeutic levels of the therapeutic agent during the application period. In some embodiments, the method is effective to achieve a flux decline of less than 30% over the application period.
By a "therapeutically effective amount" is meant a sufficient amount of D1-like family of dopamine receptors agonist for use in a method for the treatment of ADPKD at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the age, body weight, general health, sex and diet of the subject; the time of administration and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well known within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of D1-like family of dopamine receptors agonist may be varied over a wide range from 0.01 to 5,000 mg per adult per day. Typically, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the D1-like family of dopamine receptors agonist for the symptomatic adjustment of the dosage to the subject to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, typically from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. In some embodiment, the administration by transdermal patch is at a daily dosage of D1-like family of dopamine receptors agonist which may be varied over a wide range from 1 à 20 mg/cm2 per adult per day. In particular, ADPKD patients receive the D1-like family of dopamine receptors agonist using the continuous systemic delivery (e.g transdermal patch or pump) at the dose of 1, 2, 3, 4 or 5 mg per day. The D1-like family of dopamine receptors agonist as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as
biodegradable polymers, to form pharmaceutical compositions. "Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention. FIGURES: Figure 1: In a prospective parallel study, patients with autosomal dominant polycystic kidney disease (ADPKD) were randomized to receive the dopaminergic receptor agonist rotigotine at the dose of 4 mg per day (n=9) or were not treated (0 mg ; n=10). Exploration visits were performed at baseline before (V0), 1 week (V1) and 8 weeks (V2) after randomization. Endothelium-dependent flow-mediated dilatation of the radial artery, assessed by echotracking coupled to Doppler (A), and nitric oxide (NO) release, estimated by the measurement of the NO metabolite nitrite by a chemiluminescent-based assay (B), in response to hand skin heating, aortic pulse pressure (C) did not change during follow-up in non-treated ADPKD patients. However, flow-mediated dilatation increased in patients treated with 4-mg rotigotine and this was associated with an increase in NO release after 8 weeks of treatment. In addition, there was a decrease in aortic pulse pressure after 8 week of treatment with 4-mg rotigotine. Figure 2: To specifically assess the role of endothelial polycystin independently from the non- specific consequences of the kidney disease C57/Bl6J mouse transgenic models with an endothelial cell-specific inducible knockout of Pkd1 (VE-Cadh/Pkd1fl/fll) have been developed. Compared to control mice with maintained endothelial expression of polycystin-1 (Pkd1fl/fl), VE-Cadh/Pkd1fl/fl had a decreased mesenteric artery endothelium-dependent dilatation in response to stepwise increase in flow assessed by arteriography (A) and an increased blood pressure measured by tail-cuff plethysmography (B). The administration of the dopaminergic agonist fenoldopam during 14 days using osmotic minipumps (20 mmol/g/day) allowed to improve endothelium-dependent dilatation and to normalize blood pressure in VE- Cadh/Pkd1fl/fl. *P<0.05 vs. VE-Cadh/Pkd1fl/fl.
Figure 3: Representative scanning electron micrographs of the endothelial surface of the length of the endothelial protrusions, including microvilli and primary cilia obtained in Pkd1lox/lox, iCdh5-cre/ERT2-Pkd1del/del mice receiving or not fenoldopam (4 µg/kg/h) during 4 weeks. Group effect was determined by one-way ANOVA followed by Bonferroni's post hoc test. Three animals per group were used (Pkd1lox/lox: n=265 values; iCdh5-cre/ERT2-Pkd1del/del: n=239; iCdh5-cre/ERT2-Pkd1del/del + fenoldopam: n=383). ***P<0.001 vs. Pkd1lox/lox. †††P<0.001 vs. Pkd1del/del. MATERIAL AND METHODS Clinical study Population ADPKD patients were carefully selected among patients followed in the Departments of Nephrology in Rouen University Hospital, Dieppe Hospital and Le Havre Hospital. The diagnosis was made according to Pei criteria21. In addition, molecular testing of ADPKD was performed by direct sequencing, followed by quantitative fluorescent multiplex PCR or array- comparative genomic hybridization22. Only ADPKD patients aged between 18 and 60 years, with a controlled HTN [supine systolic/diastolic blood pressure (BP) <140/90 mmHg] and a glomerular filtration rate (GFR), determined by CKD-EPI formula, >45 ml/min/1.73 m2 were included. All patients received the standard-of-care support defined by KDIGO guidelines at inclusion, with BP target <140/90 mmHg (or 130/80 mmHg if presence of diabetes, proteinuria>0.5 g/24h, heart failure or left ventricular hypertrophy) and use of renin angiotensin system blockers in first intention, body mass index (BMI) target between 20 and 25 kg/m2, NaCl intake target <5 g/day, and advice for a regular physical activity.23 This study was approved by the local Ethics Committee (Committee for the Protection of Persons Nord-Ouest I), and all participants gave written informed consent. The study was conducted in accordance with the principles of good clinical practice and the declaration of Helsinki and was registered at https://eudract.gov under the unique identifier 2016-003393-40. Study design This was a prospective parallel randomized trial with blind evaluation of primary and secondary endpoints. Ten to thirty days after the visit of inclusion (V1), patients participated to a first exploration visit (V2) in the Department of Pharmacology of Rouen University Hospital and
were randomized in groups: a control group of patients on standard care who did not receive rotigotine and a group of patients on standard care and receiving rotigotine at the dose of 4 mg/24h. According to treatment escalation guidelines, patients randomized in the 4 mg/24h group received rotigotine at 2 mg/24h during 7 days and then 4 mg/24h. A second exploration visit (V3) including safety assessment was performed 7 days after randomization. A phone call was performed for patients receiving the dose of 4 mg/24h since 7 days to verify tolerance to dose escalation. A third exploration visit (V4) with safety assessment was performed fifty to sixty days after the first one. Then, patients in the 4 mg/24h group received rotigotine at the dose of 2 mg/24h during 7 days before stopping treatment. An end of the study visit (V5) was performed in all patients 10 to 20 days after the last exploration visit in the Department of Nephrology of Rouen University Hospital (Data no shown) in particular to verify the tolerance to treatment withdrawal. Exploration visits On the day of exploration, measurements were performed at least one hour after a fat-free meal while subjects were in a supine position, in a quiet air-conditioned room, maintained at a constant temperature (22 to 24°C). Subjects were asked to refrain from smoking from the previous evening. A physical examination was performed; brachial artery BP and heart rate were measured on the right arm three times using a brachial cuff oscillometric device (Omron 705IT). Radial artery waveforms of the same arm were recorded non-invasively by applanation tonometry and analyzed by using a dedicated software (Sphygmocor, Atcor Medical), allowing to calculate an averaged radial artery waveform and derive a corresponding central aortic pressure waveform using a validated generalized transfer function.24 Aortic pressure waveforms were subjected to further analysis by the Sphygmocor software to identify the time to the shoulder of the first and second pressure wave components during systole. The pressure at the shoulder of the first component was identified as P1 height (forward pressure wave), and the pressure difference between this point and the maximal pressure during systole (augmentation: ∆P) was identified as the reflected pressure wave. Augmentation index (AIx), an index of cardiovascular coupling, was defined as the ratio of augmentation to central pulse pressure: AIx=(∆P/PP) x100, where PP is pulse pressure. In addition, carotid-femoral pulse wave velocity, indicator of aortic stiffness, was assessed (Sphygmocor). Thereafter, the distal skin heating procedure was performed by introducing the right hand in a water-filled thermocontrolled tank.13 The device was then filled with water and the temperature
was fixed to 34°C for 20 min to establish baseline conditions. Then, hand skin heating was performed by gradually increasing the water temperature from 34°C to 44°C, with each level of temperature maintained for 7 min.25 Radial artery diameter and blood flow were measured during the last minute of each step by high-resolution echotracking coupled to a Doppler system (Artlab System, Esaote). The radial artery endothelium-independent dilatation was assessed using 0.3 mg of sublingual glyceryl trinitrate. Blood samples were drawn at 34°C for standard biochemistry analyses and the determination of total blood viscosity using a cone-plate viscometer (Ex100 CTB, Brookfield). From the individual values of radial artery diameter (d), flow (Q), and total blood viscosity (µ), the mean arterial wall shear stress was calculated based on a Poiseuille model, that is ^^^^= ¼ [(4µQ)/( ^^^^r3), (r=d/2)].25 In addition, additional local blood sampling was performed at 34 and 44°C for the quantification of the endothelial factors involved in FMD as previously described.13 Plasma levels of nitrite that represent NO bioavailability were determined using a tri-iodide/ozone based chemiluminescence assay. In addition, plasma levels of epoxyeicosatrienoic acids (EETs) and their metabolites dihydroxyecosatrienoic acids (DHETs) were assessed by liquid chromatography coupled to tandem mass spectrometry. EETs+DHETs was used as an index of EETs production. In addition, at the first and last exploration visits, urinary samples were collected allowing to quantify, using commercially available assays, the levels of cAMP (Cat. No: 581001, Cayman), AQP-2 (Cat. No: MBS2019939, MyBioSource) and copeptin, which is secreted in an equimolar amount to vasopressin, as well as the levels of monocyte chemoattractant protein-1 (MCP-1; Cat. No: DCP00, R&D Systems) that was identified as a prognostic biomarker of renal evolution26. Levels were adjusted to urine creatinine values. Statistics Sample size calculation The primary endpoint of the study was the change over 2 months in NO release, assessed using plasma nitrite, during hand skin heating. The number of subjects was determined by a nonparametric Kruskall-Wallis test comparing this change between groups, assuming a similar change with a similar variance than previously observed with dopamine infusion (17.3±8.8 nmol/L).13 A target sample size of 8 patients in each group was thus needed to demonstrate a significant difference between the control group and at least one treated group with 90% power
and a 5% significance level. A maximal number of ADPKD patients to include was fixed to 10 per group based on a trial exit rate not greater than 20%, which is the average rate of trial exits due to adverse events related to 1-year treatment with low-dose rotigotine in patients with restless legs syndrome.27,28 Analysis Analyses were performed using the R software (version 4.0.5 et version 1.1.463 of RStudio). Continuous variables are presented as mean±SD in the text, unless differently indicated. Qualitative variables are presented as absolute and relative frequencies. Baseline demographic and clinical data were analyzed using a non-parametric Kruskal-Wallis test, followed by a Dunn test in case of significance, and Fisher’s exact tests as appropriate. To answer to the main and secondary objectives, the difference of the variations of the parameters between the first and last exploration visits were calculated for each subject and then compared by a non-parametric Kruskal Wallis test, followed by a Dunn test in case of significance. A Bonferroni correction for multiple comparisons was also used. To characterize and compare the evolution of the parameters over the three exploration visits between groups, a repeated measures analysis was performed. A linear mixed model was estimated with an adapted variance-covariance matrix structure that minimized the AIC and BIC criteria. If the assumptions about the distributions were not met, a nonlinear mixed model could be used by transforming the parameter values in the log scale. On each graph, we presented mean±SEM for the parameter of interest at each exploration visit within each treatment group and p-value of the test for interaction term between time and treatment groups. And if the latter was significant, pairwise comparisons were realized between different exploration visit within each treatment group, taking into account multiple comparisons by a Bonferroni correction for p-values. A value of p<0.05 was considered statistically significant. Experimental studies Animals Experiments were performed in male mice in accordance with the standards and ethical rules, and with approval by the national animal ethics committee (CENOMEXA C2EA-54). Endothelial-specific knock-out of Pkd1 was generated using a tamoxifen inducible cre-loxP recombination system, on a C57BL/6J genetic background as previously described29. Homozygous iCdh5-cre/ERT2-Pkd1del/del and control Pkd1lox/lox male mice, all identically exposed to tamoxifen, were used.
Acute effect of fenoldopam The mesenteric artery relaxation to the peripheral DR agonist fenoldopam (Sigma SM20198) was studied using a small vessel myograph29, before and after addition of the specific antagonist of the DR5 receptor LE-PM43629 in iCdh5-cre/ERT2-Pkd1del/del and Pkd1lox/lox mice. In addition, the impact of chronic kidney disease induced by subtotal nephrectomy29 on fenoldopam-induced relaxation was studied in iCdh5-cre/ERT2-Pkd1del/del mice. Briefly, after sacrifice, the mesentery was removed and placed in cold oxygenated Krebs buffer. A 1.5-2.0 mm segment of first order of mesenteric resistance artery segment was mounted on a myograph (DMT, Aarhus). After normalization, relaxation to fenoldopam (10-9 to 10-5 M) was evaluated in segments precontracted with phenylephrine (Phe: 10-5 M). Furthermore, the impact of 30- min pretreatment with fenoldopam (10-6 M) on mesenteric artery FMD was studied in iCdh5- cre/ERT2-Pkd1del/del. For this, a 2-3 mm segment of third mesenteric resistance artery segment was mounted on an arteriograph (DMT).29,30 The dilatory response to stepwise increases in intraluminal flow (from 3 to 100 µL/min) was assessed in vessels precontracted with Phe (10-5 M). Chronic effect of fenoldopam The impact of 4-week fenoldopam continuous infusion using subcutaneous osmotic pumps (Alzet; 4 µg/kg//h) was studied in iCdh5-cre/ERT2-Pkd1del/del mice. A group of Pkd1lox/lox mice was used as control. Before sacrifice, non-invasive measurements of systolic BP were performed by tail-cuff plethysmography (CODA, Kent Scientific Corporation) in conscious and trained mice, and consisted in 2 series of 10 cycles of measurements. After animal sacrifice, mesenteric artery FMD was evaluated in segments precontracted with Phe as described above. In addition, scanning electron microscopy was performed on mouse aortic arch to assess the ultrastructure of the endothelium. Briefly, mice were perfused with a solution of paraformaldehyde 4%, glutaraldehyde 0.5% and HEPES buffer (Sigma) 0.2 mM pH 7.4. Segments of the aortic arch were dissected and fixed overnight in glutaraldehyde 2.5% + HEPES 0.2 mM pH 7.4 + lanthanum 2% (Sigma). The samples were thereafter fixed 1h in OSO4 1% (EMS) at 4°C. Dehydration was performed by graded series of ethanol. Complete dehydration was achieved by immersion in HMDS (Sigma) and air-dried. Samples were fixed on stub with carbon glue and were covered with 10 nm platin (PECS-Gatan-Ametek). Observations were performed on a SEM-JEOL 7900 (JEOL), with 10kV acceleration, using an Everhart-Thornley electron detector.
EXAMPLE: EXAMPLE 1: Introduction Preliminary results obtained using acute local infusion of dopamine (Lorthioir et al, Kidney International 2014) suggested that stimulating peripheral dopaminergic receptors may prevent the alteration in vascular function of patients with autosomal dominant polycystic kidney disease (ADPKD). The aim of this clinical trial was to assess the interest of the chronic stimulation of dopaminergic receptor stimulation at the vascular level Methods A prospective parallel study was performed in patients with autosomal dominant polycystic kidney disease (ADPKD) in the Departments of Clinical Pharmacology and Nephrology of Rouen University Hospital, France. After inclusion, ADPKD patients were randomized to receive the dopaminergic receptor agonist rotigotine continuously administered using transdermal patches at the dose 4 mg per day (n=10) or were not treated (n=9). Exploration visits were performed at baseline before (V0), 1 week (V1) and 8 weeks (V2) after randomization to assess endothelium-dependent flow-mediated dilatation of the radial artery, using echotracking coupled to Doppler, and nitric oxide (NO) release, estimated by the measurement of the NO metabolite nitrite using a chemiluminescent-based assay. In addition, aortic pulse pressure was measured using aplanation tonometry. Results Figures 1A-1C: Endothelium-dependent flow-mediated dilatation, NO release and blood pressure did not change during follow-up in non-treated ADPKD patients. However, flow- mediated dilatation increased in patients treated with 4-mg rotigotine and this was associated with an increase in NO release after 8 weeks of treatment. In addition, there was a decrease in aortic pulse pressure after 8 week of treatment with 4-mg rotigotine. Conclusion These results demonstrate that the chronic stimulation of dopaminergic receptors in ADPKD patients with rotigotine improves vascular endothelial function and central hemodynamics,
representing thus a new therapeutic option for the clinical management of hypertension and cardiovascular complications in this population. EXAMPLE 2: Introduction Preliminary results obtained using acute local infusion of dopamine (Lorthioir et al, Kidney International 2014) suggested that stimulating peripheral dopaminergic receptors may prevent the alteration in vascular function of patients with autosomal dominant polycystic kidney disease (ADPKD). The aim of this experimental study was to assess the interest of the chronic stimulation of dopaminergic receptor stimulation independently from non-specific consequences of this approach on kidney disease. Methods C57/Bl6J mouse transgenic models with an endothelial cell-specific inducible knockout of Pkd1 (VE-Cadh/Pkd1fl/fll) have been developed and these mice were treated with the dopaminergic agonist fenoldopam during 14 days using osmotic minipumps (20 mmol/g/day). Mesenteric artery endothelium-dependent dilatation in response to stepwise increase in flow was assessed by arteriography and blood pressure was measured by tail-cuff plethysmography. Results Figures 2A-2B: Compared to control mice with maintained endothelial expression of polycystin-1, mice with endothelial deletion of polycystin-1 had a decreased endothelium- dependent dilatation and an increased blood pressure. The administration of fenoldopam allowed to improve endothelium-dependent dilatation and to normalize blood pressure in mice with endothelial deletion of polycystin-1. Conclusion These results demonstrate that the chronic stimulation of dopaminergic receptors with fenoldopam improves vascular function and decreases blood pressure in mice with a specific endothelial deletion of polycystin-1, representing thus a new therapeutic option for the clinical management of hypertension and cardiovascular complications of ADPKD patients.
EXAMPLE 3: Chronic effect of fenoldopam Scanning electron microscopy analysis revealed the presence of protrusions at the endothelial cell surface of the aortic arch of control mice that were mainly located in specific regions thought to be dependent of a high level shear stress (Data not shown). It was not possible to formally discriminate microvilli from primary cilia but, as previously described,14 microvilli seemed to predominate. Endothelial polycystin-1-deficient mice exhibited protrusions that were characterized by a stockier and more compact aspect compared to the control mice. In endothelial polycystin-1-deficient mice treated with fenoldopam, protrusions showed a linear aspect alike protrusions of control mice. Thus, fenoldopam corrected the decrease in the length of endothelial protrusions associated with endothelial polycystin-1-deficiency (Figure 3). REFERENCES: Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure. 1. Massella L et al, CJASN 2018;13(6):874-883 ; 2. Chebib FT et al, Kidney Int Rep 2017;2(5):913-923 ; 3. Reinecke NL et al, AJKD 2014;64(2):239-246 ; 4. Weyde W et al, Clin Nephrol 2004;61(5):344-6 ; 5. Su Q et al, Science 2018;vol.361(6406) ; 6. Harris PC et al, J Clin Invest 2015;124(6):2315-2324 ; 7. Sharif-Naeini R et al, Cell 2009;139(3):587-596 ; 8. Nauli SM et al, Circulation 2008;117(9):1161-71 ; 9. AbdouAlaiwi WA et al, Circ Res 2009;104(7):860-9 ; 10. Lorthioir A et al, Kidney Int 2015;87(2):465-72 ; 11. Yamamoto K et al, J Vis Exp 2013;11(77):e50449 ; 1 2. Schrier RW et al, JASN 2014;25(11):2399-2418 ; 13. Gildea JJ et al, Kidney Int 2014;86(1):118-126 14. Van der Heiden, K, et al, Dev. Dyn.2006;235:19–28.
Claims
CLAIMS: 1. A method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a D1-like family of dopamine receptors agonist through a continuous systemic delivery. 2. The method according to claim 1 wherein D1-like family of dopamine receptors agonist is fenoldopam. 3. The method according to claim 1 wherein D1-like family of dopamine receptors agonist is rotigotine. 4. The method according to claim 1 wherein the continuous systemic delivery is administered with a pump. 5. The method according to claim 5 wherein the pump is an osmotic pump. 6. The method according to claim 1 wherein the continuous systemic delivery is administered with a transdermal patch. 7. The method according to claim 6 wherein the transdermal patch comprises a backing layer and a release liner. 8. The method according to claim 6 wherein the transdermal patch comprises a face adhesive. 9. The method according to claim 1 wherein the continuous systemic delivery achieve sustained delivery over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, or at least about 7 days.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306320.7 | 2022-09-06 | ||
EP22306320 | 2022-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024052350A1 true WO2024052350A1 (en) | 2024-03-14 |
Family
ID=83361218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074334 WO2024052350A1 (en) | 2022-09-06 | 2023-09-05 | Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024052350A1 (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722734A (en) | 1984-04-14 | 1988-02-02 | Ferring Biotechnik, Gmbh | Device for the intermittent pulsatory application of liquid pharmaceuticals |
US5013293A (en) | 1987-05-28 | 1991-05-07 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
USRE35474E (en) | 1984-10-29 | 1997-03-11 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
WO1999055341A1 (en) * | 1998-04-27 | 1999-11-04 | Elan Pharmaceuticals, Inc. | Transdermal administration of fenoldopam |
US6337086B1 (en) | 1999-02-06 | 2002-01-08 | Dow Corning Corporation | Pressure sensitive adhesive compositions for transdermal drug delivery devices |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
WO2007041386A2 (en) | 2005-09-30 | 2007-04-12 | Vyteris, Inc. | Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch |
US20190015423A1 (en) * | 2016-03-30 | 2019-01-17 | The Trustees Of Columbia University In The City Of New York | Regulation of gene expression by modulating primary cilia length |
US20210259954A1 (en) * | 2019-11-27 | 2021-08-26 | Chapman University | Cilia-targeting nanoparticles |
-
2023
- 2023-09-05 WO PCT/EP2023/074334 patent/WO2024052350A1/en unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722734A (en) | 1984-04-14 | 1988-02-02 | Ferring Biotechnik, Gmbh | Device for the intermittent pulsatory application of liquid pharmaceuticals |
USRE35474E (en) | 1984-10-29 | 1997-03-11 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
US5328454A (en) | 1987-05-28 | 1994-07-12 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US5336168A (en) | 1987-05-28 | 1994-08-09 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
US5372579A (en) | 1987-05-28 | 1994-12-13 | Drug Delivery Systems, Inc. | Pulsating transdermal drug delivery system |
US5013293A (en) | 1987-05-28 | 1991-05-07 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
WO1999055341A1 (en) * | 1998-04-27 | 1999-11-04 | Elan Pharmaceuticals, Inc. | Transdermal administration of fenoldopam |
US6337086B1 (en) | 1999-02-06 | 2002-01-08 | Dow Corning Corporation | Pressure sensitive adhesive compositions for transdermal drug delivery devices |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
WO2007041386A2 (en) | 2005-09-30 | 2007-04-12 | Vyteris, Inc. | Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch |
US20190015423A1 (en) * | 2016-03-30 | 2019-01-17 | The Trustees Of Columbia University In The City Of New York | Regulation of gene expression by modulating primary cilia length |
US20210259954A1 (en) * | 2019-11-27 | 2021-08-26 | Chapman University | Cilia-targeting nanoparticles |
Non-Patent Citations (17)
Title |
---|
"NCBI", Database accession no. NP_000789.1 |
ABDOUALAIWI WA ET AL., CIRC RES, vol. 104, no. 7, 2009, pages 860 - 9 |
CHEBIB FT ET AL., KIDNEY INT REP, vol. 2, no. 5, 2017, pages 913 - 923 |
GILDEA JJ ET AL., KIDNEY INT, vol. 86, no. 1, 2014, pages 118 - 126 |
HARRIS PC ET AL., J CLIN INVEST, vol. 124, no. 6, 2015, pages 2315 - 2324 |
LORTHIOIR A ET AL., KIDNEY INT, vol. 87, no. 2, 2015, pages 465 - 72 |
LORTHIOIR ET AL., KIDNEY INTERNATIONAL, 2014 |
MASSELLA L ET AL., CJASN, vol. 13, no. 6, 2018, pages 874 - 883 |
NAULI SM ET AL., CIRCULATION, vol. 117, no. 9, 2008, pages 1161 - 71 |
REINECKE NL ET AL., AJKD, vol. 64, no. 2, 2014, pages 239 - 246 |
SCHRIER RW ET AL., JASN, vol. 25, no. 11, 2014, pages 2399 - 2418 |
SHARIF-NAEINI R ET AL., CELL, vol. 139, no. 3, 2009, pages 587 - 596 |
SOBIESKI ET AL.: "Handbook of Pressure-Sensitive Adhesive Technology", 1989, VAN NOSTRAND REINHOLD, article "Silicone Pressure Sensitive Adhesives", pages: 508 - 517 |
SU Q ET AL., SCIENCE, vol. 361, no. 6406, 2018 |
VAN DER HEIDEN, K ET AL., DEV. DYN., vol. 235, 2006, pages 19 - 28 |
WEYDE W ET AL., CLIN NEPHROL, vol. 61, no. 5, 2004, pages 344 - 6 |
YAMAMOTO K ET AL., J VIS EXP, vol. 11, no. 77, 2013, pages e50449 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9248104B2 (en) | Transdermal methods and systems for treating Alzheimer's disease | |
US20180110739A1 (en) | Transdermal Delivery Systems | |
JP2547726B2 (en) | Skin administration of fentanyl and device therefor | |
JP5856573B2 (en) | Transdermal delivery system | |
US11324705B2 (en) | Transdermal drug delivery system | |
CZ307857B6 (en) | A transdermal patch for administering fentanyl or an analogue of it | |
JP2010159302A (en) | Transepicutaneous administration form for treating restless leg syndrome | |
US8252320B2 (en) | Transdermal delivery system for sufentanil | |
JPH02202813A (en) | Percutaneous absorbing preparation | |
JP5900971B2 (en) | Transdermal absorption enhancer and transdermal preparation containing the same | |
JP2023506538A (en) | Transdermal therapeutic system containing agomelatine | |
WO2024052350A1 (en) | Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease | |
JP2003534368A (en) | Transdermal delivery of lazofoxifene | |
US20080145318A1 (en) | Atomoxetine formulations and associated methods | |
US20100158990A1 (en) | Transdermal method and patch for corticosteroid administration | |
CN110115710B (en) | A transdermal preparation for the treatment of asthma | |
JPH0533929B2 (en) | ||
US20080031932A1 (en) | Transdermal atomoxetine formulations and associated methods | |
JPH04202140A (en) | Percutaneously absorbable preparation | |
JP7326516B2 (en) | External medicine | |
AU2013202352B2 (en) | Transdermal delivery systems comprising bupivacaine | |
JPH05229962A (en) | Percutaneous absorption preparation | |
JP2019034905A (en) | Dehydroacetic acid-containing percutaneous absorption preparation | |
JPH05178762A (en) | Percutaneous and transmucosal absorption pharmacetical | |
JPH05148158A (en) | Promoter for epithelial cell layer permeation of medicine and percutaneous absorption pharmaceutical |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23767845 Country of ref document: EP Kind code of ref document: A1 |